The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Prefilled Syringes Market (6th Edition) by Therapeutic Area (Blood disorders, Infectious diseases, Metabolic disorders, Autoimmune disorders, Oncological disorders, Neurological disorders, Ophthalmic disorders and Other disorders), Type of Syringe (Specialty Syringes and Others) , Type of Material (Glass and Plastic), Type of Molecule (Antibody, Peptide, Protein, Small Molecule and Vaccine), and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2022

  • Pages
    911

  • View Count
    17330

Example Insights

Prefilled-Syringe-Market-Context-thumb Prefilled-Syringe-Market-List-of-Prefilled-Syringes-thumb Prefilled-Syringe-Market-Distribution-by-Barrel-Fabrication-Material-thumb Prefilled-Syringe-Market-Product-Competitiveness-Analysis-thumb Prefilled-Syringe-Market-Recent-Initiatives-thumb
Prefilled-Syringe-Market-Patent-Analysis-thumb Prefilled-Syringe-Market-Key-Opinion-Leaders-thumb Prefilled-Syringe-Market-List-of-Combination-Products-thumb Prefilled-Syringe-Market-Combination-Products-thumb Prefilled-Syringe-Market-Fill-Finish-Service-Providers-thumb.PNG
Prefilled-Syringe-Market-Big-Pharma-Initiatives-thumb Prefilled-Syringe-Market-Approved-Drugs-thumb Prefilled-Syringe-Market-Potential-Strategic-Partners-thumb Prefilled-Syringe-Market-Distribution-by-Therapeutic-Area-thumb Prefilled-Syringe-Market-Distribution-by-Type-of-Molecule-thumb

Overview

We are seeing an increased demand in the emerging markets, particularly within the BRICS nations, namely Brazil, Russia, India, China and South Africa. North Africa and the Middle East also present a similar scenario, characterized by a growth rate of 10-18% for prefilled syringes

-- Marketing Director, a large-sized company

According to the World Health Organization (WHO), the prevalence of chronic diseases, such as heart diseases, cancers and diabetes, has increased at a steady pace in recent years. It is worth highlighting that six out of ten individuals in the US are anticipated to be suffering from at least one chronic disease. Specifically, such patients are required to take medication on a daily basis, necessitating frequent hospital visits. As per a recent study conducted by the US Centers for Disease Control (CDC), the annual expense incurred by patients suffering from such disease conditions has increased at a significant rate and is estimated to be USD 3 trillion. It is also worth highlighting that, with the onset of COVID-19 pandemic and the associated restrictions, patients are not able to visit hospitals. In order to mitigate the aforementioned challenges, companies engaged in the pharmaceutical domain have developed self-administrable dosage forms to ease out the overall treatment process. In this context, it is important to mention that the rise in global population and shortage of healthcare facilities has paved the way for a wider adoption of self-administrable dosage forms, such as prefilled syringes, among the patients.

Prefilled syringes are regarded as one of the safest options amongst the available alternatives for the intravenous mode of administration, as they demonstrate increased ease of self-administration due to elimination of dosing errors, as well as minimize the time requirements. Further, these syringes serve as a primary drug container for various drug delivery systems, such as autoinjectors and pen-injectors. Presently, more than 110 drugs, in combination with prefilled syringes, are commercially available. Amongst these, close to 60% of the products target autoimmune disorders. However, the increase in demand for such self-administration solutions has led to more stringent safety regulations, resulting in an evident rise in the cost of safety systems / end products. To combat this challenge, many players are actively undertaking research initiatives focused on developing low-cost alternatives that can boost the penetration rate and uptake of prefilled syringes by the end users. We believe that the aforementioned developments are likely to fuel the ongoing innovation and growth of the prefilled syringes market in the foreseen future.

Scope of the Report

The Prefilled Syringes Market (6th Edition) by Therapeutic Area (Blood disorders, Infectious diseases, Metabolic disorders, Autoimmune disorders, Oncological disorders, Neurological disorders, Ophthalmic disorders and Other disorders), Type of Syringe (Specialty Syringes and Others) , Type of Material (Glass and Plastic), Type of Molecule (Antibody, Peptide, Protein, Small Molecule and Vaccine), and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035 report features an extensive study of the current market landscape and the likely future potential associated with the prefilled syringe market, over the next decade. The study also includes an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the report features:

  • A detailed overview of the current market landscape of players engaged in the manufacturing of prefilled syringes, based on several relevant parameters, such as year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume. 
  • An overview of the current market landscape of companies engaged in the development of drugs in prefilled syringe format, based on several relevant parameters, such as year of establishment, company size, location of headquarters, target therapeutic area, phase of development, type of drug molecule, route of administration, approval year (for marketed products), dose strength (for marketed products) and other approved dosage forms (for marketed products). 
  • A detailed product competitiveness analysis of prefilled syringes, based on supplier power (in terms of employee count and annual revenues) and key product specifications (including number of chambers and needle systems, volume of the barrel and other distinguishing features).
  • An in-depth analysis of marketed drugs / therapies and pipeline candidates that are likely to be available in prefilled syringe format in the near future, based on several relevant parameters, such as route of administration, type of drug molecule, target indication, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • A list of nearly 80 drug developers that are likely to partner with prefilled syringe manufacturers (with regard to likely collaboration opportunities for combination product development). These players have been shortlisted based on various parameters, such as pipeline strength, target therapeutic indication(s) and developer strength.
  • A review of the various prefilled syringe combination product-related initiatives undertaken by big pharma players (shortlisted on the basis of revenues generated in 2020), based on various parameters, such as current adoption (based on number of approved and under development prefilled syringe combination products) and target therapeutic area(s) and type of drug molecule.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2x2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various trial studies, number of citations, number of publications and geographical location) in this field.
  • An in-depth analysis of patents related to prefilled syringes, filed / granted, since 2015, based on several relevant parameters, such as type of patent (granted patents and patent applications), publication year, geographical location, CPC symbols, emerging focus areas, most active players (in terms of the number of patents filed / granted). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 
  • A detailed analysis of contract fill / finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologics and small molecules), and geographical location of the service provider. 
  • A detailed discussion on various safety features (add-on and integrated devices) installed in recent versions of prefilled syringes and the companies involved in developing and manufacturing such solutions.
  • An informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries / geographical regions.  
  • A brief discussion on the currently available specialty syringes, including prefilled flush syringes, prefilled diluent syringe systems and prefilled contrast agent delivery systems, along with providing details related to the various advantages offered by such devices. 
  • A detailed case study of companies engaged in the manufacturing of autoinjectors, featuring brief profiles of key players in this domain; each profile includes an overview of the firm, and information on its respective product portfolio.
  • Elaborate profiles of prominent prefilled syringe manufacturers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent prefilled syringe component manufacturers, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to evaluate the current market size and the future opportunity within the prefilled syringes market. Based on various relevant parameters, such as number of commercialized combination products, annual adoption rate, and expected pricing. We have provided an informed estimate of the likely evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of  [A] therapeutic area (blood disorders, infectious diseases, metabolic disorders, autoimmune disorders, oncological disorders, neurological disorders, ophthalmic disorders and other disorders), [B] type of syringe (specialty syringe and others), [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber),  [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographical regions (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)). 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals)
  • Gregor Kawaletz (Ex-Chief Commercial Officer, IDT Biologika)
  • Tibor Hlobik (Senior Director, Product Technology Services) and Kevin Cancelliere (Ex-Directors, Pharmaceutical Delivery Systems Marketing)
  • Marco Pederiva (Head of R&D and Product Strategy, Lonstroff)
  • Jesse Fourt (Design Director, IDEO) 
  • Anonymous (Chief Executive Officer, Small-sized Medical Device Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in the development of prefilled syringes and its components?
  • What are the most adopted configuration / attributes associated with the prefilled syringes? 
  • Which companies are actively engaged in offering fill / finish services for prefilled syringes?
  • What is the relative competitiveness of different prefilled syringes that are currently available / under development? 
  • What are the key recent initiatives undertaken by players engaged in the manufacturing of prefilled syringes? 
  • How has the overall patent landscape related to prefilled syringes evolved over the past few years?
  • What is the cost burden associated with the needlestick injuries and its preventions?
  • What is the regulatory landscape for the approval of prefilled syringes across different geographies? 
  • Which companies are actively engaged in the development of combination products using prefilled syringes?
  • What are the most prominent therapeutic areas being targeted by prefilled syringes?
  • Who are the key opinion leaders in this domain?
  • Which players are likely to partner with prefilled syringe developers in order to offer combination products?
  • What are the crucial factors that are driving the prefilled syringes market?
  • Which drugs are likely to be considered for administration in prefilled syringe format?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the prefilled syringes market in the mid to long term.

Chapter 3 provides a general overview of the prefilled syringes, including details on their origin, various affiliated components (such as barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap), fabrication material (glass and plastic), manufacturing-related information, and other critical attributes and features. Further, it highlights the opportunities associated within this domain. 

Chapter 4 An overview of the current market landscape of players engaged in the manufacturing of prefilled syringes, based on several relevant parameters, such as year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume.

Chapter 5 presents a detailed product competitiveness analysis of prefilled syringes, based on supplier power (in terms of employee count and annual revenues) and key product specifications (including number of chambers and needle systems, volume of the barrel and other distinguishing features).

Chapter 6 elaborates profiles of prominent prefilled syringe manufacturers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

Chapter 7 highlights the growing concerns associated with needlestick injuries and the various steps (including regional and global legislations) that have been taken to prevent sharps related mishaps. One of the important risk mitigation strategies covered in this chapter is the installation of safety features in upcoming versions of prefilled syringes. In addition, it provides a detailed discussion on various safety features (add-on and integrated devices) installed in recent versions of prefilled syringes and the companies engaged in development and manufacturing of such solutions.

Chapter 8 provides an informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries / geographical regions.

Chapter 9 features a detailed analysis of the key opinion leaders engaged in this domain, based on various parameters, such as (number of clinical trials, number of citations, number of publications, research gate, geographical location of the institute and research gate score).

Chapter 10 features an in-depth analysis of patents related to prefilled syringes, filed / granted, since 2015, based on several relevant parameters, such as type of patent (granted patents and patent applications), publication year, geographical location, CPC symbols, emerging focus areas, most active players (in terms of the number of patents filed / granted). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 11 provides details on the various pipeline and approved products that are being evaluated or available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. It features a detailed analysis of these drugs, based on various parameters, such as the target therapeutic area(s), phase of development, type of drug molecule, route of administration, approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers engaged in this domain, along with information on their year of establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes case studies of top two marketed drugs available in prefilled syringes, namely Humira® and Enbrel®. 

Chapter 12 features a discussion on the most commonly targeted therapeutic indications, including information on the approved / marketed injectable drug products available for the treatment of such clinical conditions (across different target therapeutic areas) and their respective biosimilars.

Chapter 13 presents an in-depth analysis of marketed drugs / therapies and pipeline candidates that are likely to be available in prefilled syringe format in the near future, based on several relevant parameters, such as route of administration, type of drug molecule, target indication, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs). Additionally, the chapter features an insightful analysis, highlighting potential strategic partners (primarily drug developers) for prefilled syringes manufacturers, based on multiple parameters, such as pipeline strength, targeted therapeutic indications, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to develop combination products.

Chapter 14 features a review of the various prefilled syringe combination product-related initiatives undertaken by big pharma players (shortlisted on the basis of revenue generated in 2020), based on various parameters, such as current adoption (based on number of approved and under development prefilled syringe combination products) and target therapeutic area(s) and type of drug molecule.

Chapter 15 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and prefilled contrast agent delivery systems. For each type of specialty syringe, we have provided a brief overview and details on the different products that are available in the market and their advantages.

Chapter 16 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advancements in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual chambered syringe systems. The chapter also highlights novel lubrication and sterilization technologies.

Chapter 17 presents an insightful market forecast analysis, highlighting the future potential of the prefilled syringes market till the year 2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of  [A] therapeutic area (blood disorders, infectious diseases, metabolic disorders, autoimmune disorders, oncological disorders, neurological disorders, ophthalmic disorders and other disorders), [B] type of syringe (specialty syringes and other syringes), [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber),  [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographical regions (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)).

Chapter 18 features a detailed discussion on the various factors that are anticipated to drive growth within the prefilled syringes market, such as the rise in preference for self-administration of medication, increase in incidence of chronic diseases, evolving patient landscape, introduction and growing adoption of biologics / biosimilars, initiatives focused on the prevention of needlestick injuries and the various potential applications of prefilled syringes. 

Chapter 19 provides a detailed SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future. 

Chapter 20 Elaborate profiles of prominent prefilled syringe component manufacturers, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

Chapter 21 A detailed analysis of contract fill / finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of several relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologics and small molecules), and geographical location of the service provider. 

Chapter 22 A detailed case study of companies engaged in the manufacturing of autoinjectors, featuring brief profiles of key players in this domain; each profile includes an overview of the firm, and information on its respective product portfolio.

Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 24 is a collection of transcripts of interviews conducted with representatives from renowned organizations that are engaged in the prefilled syringes manufacturing domain. In this chapter, we have presented the details of our conversations with Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Gregor Kawaletz (Ex-Chief Commercial Officer, IDT Biologika), Kevin Cancelliere (Senior Directors, Product Technology Services) and Tibor Hlobik (Ex-Directors, Pharmaceutical Delivery Marketing System), Marco Pederiva (Marketing & Sales Director, Lonstroff) and Anonymous (Chief Executive Officer, Small-sized Medical Device Company). 

Chapters 25 is an appendix that provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix that contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE 

1.1. Chapter Overview

1.2. Scope of the Report
1.3. Research Methodology
1.4 Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Historical Evolution of Prefilled Syringes
3.3. Benefits of Prefilled Syringes Over Traditional Injectable Devices
3.3.1. Benefits of Prefilled Syringes for Healthcare Professionals and End Users
3.3.2. Benefits of Prefilled Syringes for Manufacturers
3.3.3. Transition from Existing Dosage Forms to Prefilled Syringes

3.4. Prefilled Syringe Components

3.5. Classification of Prefilled Syringes
3.5.1. Based on Barrel Fabrication Material
3.5.1.1. Glass Barrel Prefilled Syringes
3.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
3.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes

3.5.1.2. Plastic
3.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.3. Factors Likely to Drive the Use of Plastic Barrel Prefilled Syringes

3.5.2. Based on Number of Chambers in the Barrel 
3.5.3. Based on Type of Needle System
3.5.4. Based on Type of Packaging

3.6. Critical Attributes of Prefilled Syringe Design
3.7. Key Manufacturing Steps for Prefilled Syringes
3.7.1. Production of Barrels
3.7.1.1. Glass Barrel Prefilled Syringes
3.7.1.2. Plastic Barrel Prefilled Syringes

3.7.2. Production of Syringes
3.7.3. Barrel Siliconization
3.7.4. Syringe Sterilization

3.7.5. Validation of Sterilization
3.7.6. Syringe Filling
3.7.7. Syringe Testing
3.8. Future Perspectives

4. PREFILLED SYRINGES: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Prefilled Syringes: List of Available / Under Development Devices
4.2.1. Analysis by Type of Barrel Fabrication Material
4.2.2. Analysis by Number of Barrel Chambers
4.2.3. Analysis by Type of Needle System
4.2.4. Analysis by Device Capacity

4.3. Prefilled Syringes: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Location of Manufacturing Facilities
4.3.6. Most Active Players: Analysis by Number of Products

4.4. Technological Developments Related to Prefilled Syringes

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis: Prefilled Syringes
5.4.1. Glass Barrel Prefilled Syringes
5.4.2. Plastic Barrel Prefilled Syringes

6. PREFILLED SYRINGE MANUFACTURERS
6.1. Chapter Overview
6.2. Prefilled Syringe Manufacturers Based in North America
6.2.1. Becton Dickinson
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Prefilled Syringe Portfolio
6.2.1.4. Glass Barrel Prefilled Systems
6.2.1.4.1. BD Hypak™ Prefilled Syringe
6.2.1.4.2. BD Neopak™ Prefilled Syringe
6.2.1.4.3. BD Hylok™ Prefilled Syringe
6.2.1.5. Plastic Barrel Prefilled Systems
6.2.1.5.1. BD Sterifill Syringe Systems
6.2.1.5.2 BD PosiFlush® Syringe Systems
6.2.1.6. Other Prefilled Delivery Systems
6.2.1.6.1. BD Uniject®
6.2.1.7. Future Outlook

6.2.2 Pfizer Hospital
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3 Prefilled Syringe Portfolio
6.2.2.3.1. ABBOJECT® Syringe
6.2.2.3.2. Emergency Syringe
6.2.2.3.3. iSecure™ Syringe System
6.2.2.3.4. NEXJECT™ Syringe
6.2.2.4. Future Outlook

6.2.3. West Pharmaceutical
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Prefilled Technology Solutions
6.2.3.4. Plastic Prefilled Systems
6.2.3.4.1. Daikyo Crystal Zenith® Polymer RTU Prefilled Syringe
6.2.3.5. Drug Reconstitution Systems
6.2.3.6 History of CZ Syringe
6.2.3.7. Manufacturing Focused Expansions
6.2.3.8. Future Outlook

6.3. Key Prefilled Syringe Manufacturers Based in Europe
6.3.1. Gerresheimer
6.3.1.1. Company Overview
6.3.1.2. Financial Performance
6.3.1.3. Prefilled Technology Solutions
6.3.1.4. Glass Prefilled Systems
6.3.1.4.1. Gx Glass Syringes
6.3.1.5. Plastic Prefilled Systems
6.3.1.5.1. ClearJect® Prefilled syringes
6.3.1.5.2. Gx RTF® Clearject® Needle Syringe
6.3.1.6. Safety Syringes
6.3.1.6.1. Gx InnoSafe® Safety Syringes
6.3.1.7. Self-Injection Devices
6.3.1.8. Key Developments
6.3.1.9. Future Outlook

6.3.2. Ompi 
6.3.2.1. Company Overview
6.3.2.2. Financial Performance
6.3.2.3. Glass Barrel Prefilled Systems
6.3.2.3.1. EZ-fill® Syringes
6.3.2.3.1.1. EZ-fill® Fina
6.3.2.3.1.2. EZ-fill® Nexa
6.3.2.3.1.3. EZ-fill® Alba
6.3.2.4. Key Developments
6.3.2.5. Future Outlook

6.3.3. Schott 
6.3.3.1. Company Overview
6.3.3.2. Financial Performance
6.3.3.3. Glass Barrel Prefilled Syringes
6.3.3.3.1. syriQ® Glass Syringes
6.3.3.4. Plastic Barrel Prefilled Syringes
6.3.3.4.1. TopPac® Polymer Syringes
6.3.3.5. Product Portfolio
6.3.3.5.1. SyriQ® BioPure Syrigne System for Sensitive Drugs
6.3.3.5.2. TopPac® Syringe System for Sensitive Drugs
6.3.3.5.3. TopPac® Syringe System for Highly Viscous Drugs
6.3.3.5.4. TopPac® 20mL Syringe System for Infusion Therapy
6.3.3.6. Key Developments
6.3.3.7. Future Outlook

6.4. Key Prefilled Syringe Manufacturers in Asia
6.4.1. Nipro (Acquired MGlas)
6.4.1.1. Company Overview
6.4.1.2. Financial Performance
6.4.1.3. Glass Barrel Prefilled Systems
6.4.1.4. Key Developments
6.4.1.5. Future Outlook

6.4.2. Taisei Kako
6.4.2.1. Company Overview
6.4.2.2. Glass Barrel Prefilled Systems
6.4.2.2.1. VF-Syringe
6.4.2.2.2. SIN-Syringe
6.4.2.3. Plastic Barrel Prefilled System
6.4.2.3.1. ClearJect® Syringes
6.4.2.3.2. FULJECT Passive Type Syringe
6.4.2.4. Future Outlook

6.5. Other Manufacturers
6.5.1. Aguettant
6.5.1.1. Company Overview
6.5.1.2. Prefilled Syringe Portfolio
6.5.1.2.1. Aguettant Prefilled Syringe
6.5.1.3. Key Developments
6.5.1.4. Future Outlook

6.5.2. Arte 
6.5.2.1. Company Overview
6.5.2.2. Prefilled Syringe Portfolio
6.5.2.2.1. ARTE Prefillable Syringe
6.5.2.2.2. Dual Chamber Prefillable Syringe
6.5.2.2.3. Single Chamber Prefillable Syringe
6.5.2.3. Future Outlook

6.5.3. J.O. Pharma (Subsidiary of Otsuka Holdings)
6.5.3.1. Company Overview
6.5.3.2. Prefilled Syringe Portfolio
6.5.3.3. Key Developments
6.5.3.4 Future Outlook

6.5.4. Shandong Pharmaceutical Glass
6.5.4.1. Company Overview
6.5.4.2. Prefilled Syringes Portfolio
6.5.4.3 Future Outlook

6.5.5. Shandong Zibo Minkang Pharmaceutical packing
6.5.5.1. Company Overview
6.5.5.2. Prefilled Syringes Portfolio
6.5.5.3. Future Outlook

6.5.6. Terumo 
6.5.6.1. Company Overview
6.5.6.2. Financial Performance
6.5.6.3. PLAJEX™ (Plastic Prefilled Syringe)
6.5.6.4. Safety Add-On Devices
6.5.6.5. Key Developments
6.5.6.6. Future Outlook

6.5.7. Vetter Pharma
6.5.7.1. Company Overview
6.5.7.2. Prefilled Syringe Portfolio
6.5.7.2.1. Lyo-Ject® Glass Prefilled Syringe
6.5.7.2.2. Vetter-Ject® Safety Device
6.5.7.2.3. V-OVS Safety Device
6.5.7.3. Key Developments
6.5.7.4. Future Outlook

6.5.8. WEGO Prefills Pharmaceutical Packaging
6.5.8.1. Company Overview
6.5.8.2. Financial Performance
6.5.8.3. WeGo Glass Prefilled Syringe
6.5.8.4. Weigao Prefilled Flush Syringes
6.5.8.5. Future Outlook

7. NEEDLESTICK INJURIES
7.1. Chapter Overview
7.2. Incidence and Associated Financial Burden
7.3. Government Legislations for Prevention of Needlestick Injuries

7.4. Safety Mechanisms Used in Modern Prefilled Syringes
7.4.1. Safety Systems: Add-On Safety Device Manufacturers
7.4.1.1. Becton Dickinson
7.4.1.2. Catalent 
7.4.1.3. Terumo 
7.4.1.4. Tip-Top 
7.4.1.5. West Pharmaceutical

7.4.2. Safety Systems: Integrated Safety Device Manufacturers
7.4.2.1. Gerresheimer
7.4.2.2. Injecto 
7.4.2.3. MedicalChain International
7.4.2.4. OMPI 
7.4.2.5. Owen Mumford
7.4.2.6. SHL Group
7.4.2.7. Taisei Kako

8. REGULATORY LANDSCAPE FOR PREFILLED SYRINGES
8.1. Chapter Overview
8.2. Regulatory Approval of Combination Products in the US
8.2.1. Overview
8.2.2. Historical Background
8.2.3. Role of Regulatory Bodies in Product Approval
8.2.4. Regulatory Approval for Prefilled Syringes
8.2.4.1. Reimbursement Landscape
8.2.4.2. Payer Mix
8.2.4.3. Reimbursement Process

8.3. Regulatory Approval of Combination Products in Europe
8.3.1. Overview
8.3.2. Role of Regulatory Bodies in Product Approval
8.3.3. Regulatory Approval for Prefilled Syringes

8.3.3.1. Reimbursement Landscape for the UK
8.3.3.2. Payer Mix
8.3.3.3. Reimbursement Process in the UK

8.3.3.4. Reimbursement Landscape for France
8.3.3.5. Payer Mix
8.3.3.6. Reimbursement Process in France

8.3.3.7. Reimbursement Landscape for Spain
8.3.3.8. Payer Mix
8.3.3.9. Reimbursement Process in Spain

8.3.3.10. Reimbursement Landscape for Germany
8.3.3.11. Payer Mix 
8.3.3.12. Reimbursement Process in Germany

8.3.3.13. Reimbursement Landscape for Italy
8.3.3.14. Payer Mix
8.3.3.15. Reimbursement Process in Italy

8.4. Regulatory Approval of Combination Products in Canada
8.4.1. Overview
8.4.2. Role of Regulatory Bodies in Product Approval
8.4.3. Regulatory Approval for Prefilled Syringes 
8.4.3.1. Reimbursement Landscape for Canada
8.4.3.2. Payer Mix
8.4.3.3. Reimbursement Process in Canada

8.5. Regulatory Approval of Combination Products in Brazil
8.5.1. Overview
8.5.2. Role of Regulatory Bodies in Product Approval
8.5.3. Regulatory Approval for Prefilled Syringes 
8.5.3.1. Reimbursement Landscape for Brazil
8.5.3.2. Payer Mix
8.5.3.3. Reimbursement Process in Brazil

8.6. Regulatory Approval of Combination Products in Australia
8.6.1. Overview
8.6.2. Role of Regulatory Bodies in Product Approval
8.6.3. Regulatory Approval for Prefilled Syringes 
8.6.3.1. Reimbursement Landscape for Australia
8.6.3.2. Payer Mix
8.6.3.3. Reimbursement Process in Australia

8.7. Regulatory Approval of Combination Products in Japan
8.7.1. Overview
8.7.2. Role of Regulatory Bodies in Product Approval
8.7.3. Regulatory Approval for Prefilled Syringes 
8.7.3.1. Reimbursement Landscape for Japan
8.7.3.2. Payer Mix
8.7.3.3. Reimbursement Process in Japan

8.8. Regulatory Approval of Combination Products in China
8.8.1. Overview
8.8.2. Role of Regulatory Bodies in Product Approval
8.8.3. Regulatory Approval for Prefilled syringes 
8.8.3.1. Reimbursement Landscape for China
8.8.3.2. Payer Mix
8.8.3.3. Reimbursement Process in China

8.9. Regulatory Approval of Combination Products in India
8.9.1. Overview
8.9.2. Role of Regulatory Bodies in Product Approval
8.9.3. Regulatory Approval for Prefilled Syringes 
8.9.3.1. Reimbursement Landscape for India
8.9.3.2. Payer Mix

8.10. Regulatory Approval of Combination Products in South Korea
8.10.1. Overview
8.10.2. Role of Regulatory Bodies in Product Approval
8.10.3. Regulatory Approval for Prefilled Syringes 
8.10.3.1. Reimbursement Landscape for Saudi Arabia
8.10.3.2. Payer Mix
8.10.3.3. Reimbursement Process in Saudi Arabia

8.11. Regulatory Approval of Combination Products in United Arab Emirates
8.11.1. Overview
8.11.2. Role of Regulatory Bodies in Product Approval
8.11.3. Regulatory Approval for Prefilled Syringes 
8.11.3.1. Reimbursement Landscape for United Arab Emirates
8.11.3.2. Payer Mix
8.11.3.3. Reimbursement Process in United Arab Emirates

9. PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW
9.1. Chapter Overview
9.2. Prefilled Syringe Combination Products: List of Approved Drugs
9.2.1. Analysis by Type of Drug Molecule
9.2.2. Analysis by Approval Year 
9.2.3. Analysis by Geography
9.2.4. Analysis by Route of Administration 
9.2.5. Analysis by Target Therapeutic Area
9.2.6. Prefilled Syringe Combination Products: Additional Information
9.2.6.1. Analysis by Dose Strength
9.2.6.2. Analysis by Other Approved Dosage Forms

9.3. Prefilled Syringe Combination Products: List of Clinical Stage Drugs
9.3.1. Analysis by Type of Drug Molecule 
9.3.2. Analysis by Phase of Development 
9.3.3. Analysis by Route of Administration
9.3.4. Analysis by Target Therapeutic Area

9.4. Prefilled Syringe Combination Products: List of Developers
9.4.1. Analysis by Year of Establishment
9.4.2. Analysis by Company Size
9.4.3. Analysis by Location of Headquarters

9.5. Leading Drugs Available in Prefilled Syringe Format
9.6. Other Drugs Available in Prefilled Syringe Format

9.7. Case Study of Popular Drugs Available in Prefilled Syringe Market
9.7.1. HUMIRA® (Adalimumab), AbbVie / Eisai
9.7.1.1. Target Indications and Available Dosage Forms
9.7.1.2. Shift from Vials to Syringes
9.7.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
9.7.2.1. Target Indications and Available Dosage Forms
9.7.2.2. Shift from Vials to Syringes

10. KEY THERAPEUTIC AREAS
10.1. Chapter Overview
10.1.1. Autoimmune Disorders
10.1.1.1. Approved Injectables
10.1.1.2. Biosimilars

10.1.2. Infectious Diseases
10.1.2.1. Antiviral Drugs
10.1.2.1.1. Approved Injectables
10.1.2.1.2. Biosimilars
10.1.2.2. Vaccines 
10.1.2.2.1. Approved Injectables

10.1.3. Neurological Disorders
10.1.3.1. Approved Injectables
10.1.3.2. Biosimilars

10.1.4. Metabolic Disorders
10.1.4.1. Approved Injectables
10.1.4.2. Biosimilars

11. PREFILLED SYRINGES: LIKELY DRUG CANDIDATES AND PARTNER   ANALYSIS
11.1. Chapter Overview
11.2. Likely Drug Candidates
11.2.1. Methodology and Key Parameters

11.3. Marketed Drug Candidates
11.3.1. Most Likely Candidates for Delivery via Prefilled Syringes
11.3.2. Likely Candidates for Delivery via Prefilled Syringes
11.3.3. Less Likely Candidates for Delivery via Prefilled Syringes
11.3.4. Least Likely Candidates for Delivery via Prefilled Syringes

11.4. Clinical Drug Candidates
11.4.1. Most Likely Candidates for Delivery via Prefilled Syringes
11.4.2. Likely Candidates for Delivery via Prefilled Syringes
11.4.3. Less Likely Candidates for Delivery via Prefilled Syringes
11.4.4. Least Likely Candidates for Delivery via Prefilled Syringes

11.5. Potential Strategic Partners
11.5.1. Methodology and Key Parameters
11.5.2. Potential Strategic Partners in North America
11.5.2.1. Most Likely Partners for Prefilled Syringes Combination Products
11.5.2. 2. Likely Partners for Prefilled Syringes Combination Products
11.5.2.3. Less Likely Partners for Prefilled Syringes Combination Products
11.5.2.4. Least Likely Partners for Prefilled Syringes Combination Products

11.5.3. Potential Strategic Partners in Europe
11.5.3.1. Most Likely Partners for Prefilled Syringes Combination Products
11.5.3.2. Likely Partners for Prefilled Syringes Combination Products
11.5.3.3. Less Likely Partners for Prefilled Syringes Combination Products
11.5.3.4. Least Likely Partners for Prefilled Syringes Combination Products

11.5.4. Potential Strategic Partners in Asia-Pacific and Rest of the World
11.5.4.1. Most Likely Partners for Prefilled Syringes Combination Products
11.5.4.2. Likely Partners for Prefilled Syringes Combination Products
11.5.4.3. Less Likely Partners for Prefilled Syringes Combination Products
11.5.4.4. Least Likely Partners for Prefilled Syringes Combination Products

12. BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS
12.1. Chapter Overview
12.2. Methodology
12.3. Key Pharmaceutical Companies
12.3.1. Analysis by Therapeutic Area
12.3.1.1. Autoimmune Disorders
12.3.1.2. Infectious Diseases
12.3.1.3. Oncological Disorders
12.3.1.4. Metabolic Disorders
12.3.1.5. Neurological Disorders
12.3.1.6. Inflammatory Disorders
12.3.1.7. Orthopedic Disorders
12.3.1.8. Cardiovascular Disorders
12.3.1.9. Respiratory Disorders
12.3.1.10. Ophthalmic Disorders
12.3.1.11. Others 

12.3.2. Analysis by Type of Molecule
12.3.2.1. Antibodies
12.3.2.2. Vaccines 
12.3.2.3. Proteins 
12.3.2.4. Small Molecules
12.3.2.5. Peptides 
12.3.2.4. Others 

13. RECENT DEVELOPMENTS
13.1. Chapter Overview
13.2. List of Recent Initiatives Related to Prefilled Syringes, 2019-2021
13.3. Analysis by Year of Initiative
13.4. Analysis by Type of Initiative
13.5. Analysis by Year and Type of Initiative
13.5.1 Analysis by Type of Expansion
13.5.2 Analysis by Type of Investment and Funding
13.5.3 Analysis by Type of Partnership
13.6. Analysis by Geography
13.7. Most Active Players: Distribution by Number of Initiatives
13.8. Analysis of Player by Type of Instances

14. PATENT ANALYSIS
14.1 Chapter Overview
14.2. Patent Analysis: Prefilled Syinges
14.2.1. Scope and Methodology
14.2.2. Analysis by Publication Year
14.2.3. Analysis by Publication Year and Type of Patent
14.2.4. Analysis by Geography
14.2.5. Analysis by CPC Symbols
14.2.6. Analysis by Emerging Focus Area
14.2.7. Most Active Players: Analysis by Number of Patents
14.2.8. Patent Benchmarking Analysis
14.2.9. Overall Intellectual Property Portfolio: Analysis by Type of Organization
14.2.10. Patent Valuation Analysis

15. SPECIALTY PREFILLED SYRINGES
15.1. Chapter Overview
15.2. Prefilled Flush Syringes
15.2.1. Overview
15.2.2. Prefilled Flush Syringes Available in the Market
15.2.3. Advantages of Prefilled Flush Syringes

15.3. Prefilled Diluent Syringes
15.3.1. Overview
15.3.2. Lyophilized Drugs Available in Prefilled Diluent Syringes
15.3.3. Advantages of Prefilled Diluent Syringes

15.4. Contrast Agent Prefilled Syringes
15.4.1. Overview
15.4.2. Contrast Agents Available in Prefilled Syringes
15.4.3. Advantages of Contrast Agents Used in Prefilled Syringes 

16. TECHNOLOGICAL ADVANCES RELATED TO PREFILLED SYRINGE
16.1. Chapter Overview
16.2. Prefilled Syringes for Lyophilized Drugs
16.2.1. Prefilled Diluent Syringes
16.2.2. Prefilled Dual / Multi-Chamber Prefilled Syringes
16.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringes
16.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilized Drugs

16.3. Prefilled Syringes for Ophthalmic Administration
16.4. Prefilled Syringes for Dermal Fillers
16.5. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
16.6. Prefilled Syringes with Low Particle Formation Risk
16.7. Lubrication Technology for Prefilled Syringes

16.8. Advances in Terminal Sterilization of Prefilled Syringes
16.8.1. Noxilizer’s Nitrogen Dioxide Sterilization Technology
16.9. Prefilled Syringe Usage Aids for Patients and Healthcare Providers

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Global Prefilled Syringes Market, 2022-2035
17.3.1. Prefilled Syringes Market: Analysis by Therapeutic Area
17.3.1.1. Prefilled Syringes Market for Autoimmune Disorders, 2022-2035
17.3.1.2. Prefilled Syringes Market for Infectious Diseases, 2022-2035
17.3.1.3. Prefilled Syringes Market for Neurological Disorders, 2022-2035
17.3.1.4. Prefilled Syringes Market for Blood Disorders, 2022-2035
17.3.1.5. Prefilled Syringes Market for Oncological Disorders, 2022-2035
17.3.1.6. Prefilled Syringes Market for Psychiatric Diseases, 2022-2035
17.3.1.7. Prefilled Syringes Market for Respiratory Disorders, 2022-2035
17.3.1.8. Prefilled Syringes Market for Cardiovascular Disorders, 2022-2035
17.3.1.9. Prefilled Syringes Market for Metabolic Disorders, 2022-2035
17.3.1.10. Prefilled Syringes Market for Ophthalmic Disorder, 2022-2035
17.3.1.11. Prefilled Syringes Market for Orthopedic Disorders, 2022-2035
17.3.1.12. Prefilled Syringes Market for Other Diseases, 2022-2035

17.3.2. Prefilled Syringes Market: Analysis by Type of Syringe Barrel Material
17.3.2.1. Prefilled Syringes Market for Glass Barrel Prefilled Syringes, 2022-2035
17.3.2.2. Prefilled Syringes Market for Plastic Barrel Prefilled Syringes, 2022-2035

17.3.3. Prefilled Syringes Market: Analysis by Type of Chamber System
17.3.3.1. Prefilled Syringes Market for Single Chamber Prefilled Syringes, 2022-2035
17.3.3.2. Prefilled Syringes Market for Dual Chamber Prefilled Syringes, 2022-2035

17.3.4. Prefilled Syringes Market: Analysis by Type of Drug Molecule
17.3.4.1. Prefilled Syringes Market for Antibodies, 2022-2035
17.3.4.2. Prefilled Syringes Market for Proteins, 2022-2035
17.3.4.3. Prefilled Syringes Market for Peptides, 2022-2035
17.3.4.4. Prefilled Syringes Market for Small Molecules, 2022-2035
17.3.4.5. Prefilled Syringes Market for Vaccines, 2022-2035

17.3.5. Prefilled Syringes Market: Analysis by Geography
17.3.5.1. Prefilled Syringes Market for North America, 2022-2035
17.3.5.2. Prefilled Syringes Market for Europe, 2022-2035
17.3.5.3. Prefilled Syringes Market for Asia Pacific, 2022-2035
17.3.5.4. Prefilled Syringes Market for Latin America, 2022-2035
17.3.5.5. Prefilled Syringes Market for Middle East and Africa, 2022-2035

17.3.6. Prefilled Syringes Market: Analysis by Specialty Syringes
17.3.7. Prefilled Syringes Market for Autoimmune Disorders, 2022-2035
17.3.7.1. Prefilled Syringes Market for Autoimmune Disorders: Analysis by Syringe Barrel Material
17.3.7.1.1. Glass Barrel Prefilled Syringes Market for Autoimmune Disorders
17.3.7.1.2. Plastic Barrel Prefilled Syringes Market for Autoimmune Disorders
17.3.7.2. Prefilled Syringes Market for Autoimmune Disorders: Analysis by Type of Chamber System
17.3.7.2.1. Single Chamber Prefilled Syringes Market for Autoimmune Disorders
17.3.7.2.2. Dual Chamber Prefilled Syringes Market for Autoimmune Disorders
17.3.7.3. Prefilled Syringes Market for Autoimmune Disorders: Analysis by Type of Drug Molecule
17.3.7.3.1. Antibodies Market for Autoimmune Disorders
17.3.7.3.2. Proteins Market for Autoimmune Disorders
17.3.7.3.3. Small Molecules Market for Autoimmune Disorders
17.3.7.4. Prefilled Syringes Market for Autoimmune Disorders: Analysis by Geography
17.3.7.4.1. North America Market for Autoimmune Disorders
17.3.7.4.2. Europe Market for Autoimmune Disorders
17.3.7.4.3. Asia Pacific Market for Autoimmune Disorders
17.3.7.4.4. Latin America Market for Autoimmune Disorders
17.3.7.4.5. Middle East and Africa Market for Autoimmune Disorders

17.3.8. Prefilled Syringes Market for Infectious Disorders, 2022-2035
17.3.8.1. Prefilled Syringes Market for Infectious Disorders: Analysis by Type of Syringe Barrel Material
17.3.8.1.1. Glass Barrel Prefilled Syringes Market for Infectious Disorders
17.3.8.1.2. Plastic Barrel Prefilled Syringes Market for Infectious Disorders
17.3.8.2. Prefilled Syringes Market for Infectious Disorders: Analysis by Type of Chamber System
17.3.8.2.1. Single Chamber Prefilled Syringes Market for Infectious Disorders
17.3.8.2.2. Dual Chamber Prefilled Syringes Market for Infectious Disorders
17.3.8.3. Prefilled Syringes Market for Infectious Disorders: Analysis by Type of Drug Molecule
17.3.8.3.1. Vaccines Market for Infectious Disorders
17.3.8.4. Prefilled Syringes Market for Infectious Disorders: Analysis by Geography
17.3.8.4.1. North America Market for Infectious Disorders
17.3.8.4.2. Europe Market for Infectious Disorders
17.3.8.4.3. Asia Pacific Market for Infectious Disorders
17.3.8.4.4. Latin America Market for Infectious Disorders
17.3.8.4.5. Middle East and Africa Market for Infectious Disorders

17.3.9. Prefilled Syringes Market for Neurological Disorders, 2022-2035
17.3.9.1. Prefilled Syringes Market for Neurological Disorders: Analysis by Type of Syringe Barrel Material
17.3.9.1.1. Glass Barrel Prefilled Syringes Market for Neurological Disorders
17.3.9.1.2. Plastic Barrel Prefilled Syringes Market for Neurological Disorders
17.3.9.2. Prefilled Syringes Market for Neurological Disorders: Analysis by Type of Chamber System
17.3.9.2.1. Single Chamber Prefilled Syringes Market for Neurological Disorders
17.3.9.2.2. Dual Chamber Prefilled Syringes Market for Neurological Disorders
17.3.9.3. Prefilled Syringes Market for Neurological Disorders: Analysis by Type of Drug Molecule
17.3.9.3.1. Antibodies Market for Neurological Disorders
17.3.9.3.2. Proteins Market for Neurological Disorders
17.3.9.3.3. Peptides Market for Neurological Disorders
17.3.9.4. Prefilled Syringes Market for Neurological Disorders: Analysis by Geography
17.3.9.4.1. North America Market for Neurological Disorders
17.3.9.4.2. Europe Market for Neurological Disorders
17.3.9.4.3. Asia Pacific Market for Neurological Disorders
17.3.9.4.4. Latin America Market for Neurological Disorders
17.3.9.4.5. Middle East and Africa Market for Neurological Disorders

17.3.10. Prefilled Syringes Market for Blood Disorders, 2022-2035
17.3.10.1. Prefilled Syringes Market for Blood Disorders: Analysis by Type of Syringe Barrel Material
17.3.10.1.1. Glass Barrel Prefilled Syringes Market for Blood Disorders
17.3.10.1.2. Plastic Barrel Prefilled Syringes Market for Blood Disorders
17.3.10.2. Prefilled Syringes Market for Blood Disorders: Analysis by Type of Chamber System
17.3.10.2.1. Single Chamber Prefilled Syringes Market for Blood Disorders
17.3.10.2.2. Dual Chamber Prefilled Syringes Market for Blood Disorders
17.3.10.3. Prefilled Syringes Market for Blood Disorders: Analysis by Type of Drug Molecule
17.3.10.3.1. Proteins Market for Blood Disorders
17.3.10.3.2. Small Molecules Market for Blood Disorders
17.3.10.4. Prefilled Syringes Market for Blood Disorders: Analysis by Geography
17.3.10.4.1. North America Market for Blood Disorders
17.3.10.4.2. Europe Market for Blood Disorders
17.3.10.4.3. Asia Pacific Market for Blood Disorders
17.3.10.4.4. Latin America Market for Blood Disorders
17.3.10.4.5. Middle East and Africa Market for Blood Disorders

17.3.11. Prefilled Syringes Market for Oncological Disorders, 2022-2035
17.3.11.1. Prefilled Syringes Market for Oncological Disorders
: Analysis by Type of Syringe Barrel Material  
17.3.11.1.1. Glass Barrel Prefilled Syringes Market for Oncological Disorders
17.3.11.1.2. Plastic Barrel Prefilled Syringes Market for Oncological Disorders
17.3.11.2. Prefilled Syringes Market for Oncological Disorders: Analysis by Type of Chamber System
17.3.11.2.1. Single Chamber Prefilled Syringes Market for Oncological Disorders
17.3.11.2.2. Dual Chamber Prefilled Syringes Market for Oncological Disorders
17.3.11.3. Prefilled Syringes Market for Oncological Disorders: Analysis by Type of Drug Molecule
17.3.11.3.1. Antibodies Market for Oncological Disorders
17.3.11.3.2. Proteins Market for Oncological Disorders
17.3.11.3.3. Peptides Market for Oncological Disorders
17.3.11.3.4. Small Molecules Market for Oncological Disorders
17.3.11.3.5. Vaccines Market for Oncological Disorders
17.3.11.4. Prefilled Syringes Market for Oncological Disorders: Analysis by Geography
17.3.11.4.1. North America Market for Oncological Disorders
17.3.11.4.2. Europe Market for Oncological Disorders
17.3.11.4.3. Asia Pacific Market for Oncological Disorders
17.3.11.4.4. Latin America Market for Oncological Disorders
17.3.11.4.5. Middle East and Africa Market for Oncological Disorders
  
17.3.12. Prefilled Syringes Market for Metabolic Disorders, 2022-2035
17.3.12.1. Prefilled Syringes Market for Metabolic Disorders: Analysis by Type of Syringe Barrel Material
17.3.12.1.1. Glass Barrel Prefilled Syringes Market for Metabolic Disorders
17.3.12.1.2. Plastic Barrel Prefilled Syringes Market for Metabolic Disorders
17.3.12.2. Prefilled Syringes Market for Metabolic Disorders: Analysis by Type of Chamber System
17.3.12.2.1. Single Chamber Prefilled Syringes Market for Metabolic Disorders
17.3.12.2.2. Dual Chamber Prefilled Syringes Market for Metabolic Disorders
17.3.12.3. Prefilled Syringes Market for Metabolic Disorders: Analysis by Type of Drug Molecule
17.3.12.3.1. Proteins Market for Metabolic Disorders
17.3.12.3.2. Peptides Market for Metabolic Disorders
17.3.12.4. Prefilled Syringes Market for Metabolic Disorders: Analysis by Geography
17.3.12.4.1. North America Market for Metabolic Disorders
17.3.12.4.2. Europe Market for Metabolic Disorders
17.3.12.4.3. Asia Pacific Market for Metabolic Disorders
17.3.12.4.4. Latin America Market for Metabolic Disorders
17.3.12.4.5. Middle East and Africa Market for Metabolic Disorders

17.3.13. Prefilled Syringes Market for Respiratory Disorders, 2022-2035
17.3.13.1. Prefilled Syringes Market for Respiratory Disorders: Analysis by Type of Syringe Barrel Material
17.3.13.1.1. Glass Barrel Prefilled Syringes Market for Respiratory Disorders
17.3.13.1.2. Plastic Barrel Prefilled Syringes Market for Respiratory Disorders
17.3.13.2. Prefilled Syringes Market for Respiratory Disorders: Analysis by Type of Chamber System
17.3.13.2.1. Single Chamber Prefilled Syringes Market for Respiratory Disorders
17.3.13.2.2. Dual Chamber Prefilled Syringes Market for Respiratory Disorders
17.3.13.3. Prefilled Syringes Market for Respiratory Disorders: Analysis by Type of Drug Molecule
17.3.13.3.1. Proteins Market for Respiratory Disorders
17.3.13.3.2. Peptides Market for Respiratory Disorders
17.3.13.4. Prefilled Syringes Market for Respiratory Disorders: Analysis by Geography
17.3.13.4.1. North America Market for Respiratory Disorders
17.3.13.4.2. Europe Market for Respiratory Disorders
17.3.13.4.3. Asia Pacific Market for Respiratory Disorders
17.3.13.4.4. Latin America Market for Respiratory Disorders
17.3.13.4.5. Middle East and Africa Market for Respiratory Disorders

17.3.14. Prefilled Syringes Market for Ophthalmologic Disorders, 2022-2035
17.3.14.1. Prefilled Syringes Market for Ophthalmologic Disorders: Analysis by Type of Syringe Barrel Material
17.3.14.1.1. Glass Barrel Prefilled Syringes Market for Ophthalmologic Disorders
17.3.14.1.2. Plastic Barrel Prefilled Syringes Market for Ophthalmologic Disorders
17.3.14.2. Prefilled Syringes Market for Ophthalmologic Disorders: Analysis by Type of Chamber System
17.3.14.2.1. Single Chamber Prefilled Syringes Market for Ophthalmologic Disorders
17.3.14.2.2. Dual Chamber Prefilled Syringes Market for Ophthalmologic Disorders
17.3.14.3. Prefilled Syringes Market for Ophthalmologic Disorders: Analysis by Type of Drug Molecule
17.3.14.3.1. Proteins Market for Ophthalmologic Disorders
17.3.14.3.2. Peptides Market for Ophthalmologic Disorders
17.3.14.4. Prefilled Syringes Market for Ophthalmologic Disorders: Analysis by Geography
17.3.14.4.1. North America Market for Ophthalmologic Disorders
17.3.14.4.2. Europe Market for Ophthalmologic Disorders
17.3.14.4.3. Asia Pacific Market for Ophthalmologic Disorders
17.3.14.4.4. Latin America Market for Ophthalmologic Disorders
17.3.14.4.5. Middle East and Africa Market for Ophthalmologic Disorders

17.3.15. Prefilled Syringes Market for Other Disorders, 2022-2035
17.3.15.1. Prefilled Syringes Market for Other Disorders: Analysis by Type of Syringe Barrel Material
17.3.15.1.1. Glass Barrel Prefilled Syringes Market for Other Disorders
17.3.15.1.2. Plastic Barrel Prefilled Syringes Market for Other Disorders
17.3.15.2. Prefilled Syringes Market for Other Disorders: Analysis by Type of Chamber System
17.3.15.2.1. Single Chamber Prefilled Syringes Market for Other Disorders
17.3.15.2.2. Dual Chamber Prefilled Syringes Market for Other Disorders
17.3.15.3. Prefilled Syringes Market for Other Disorders: Analysis by Type of Drug Molecule
17.3.15.3.1. Antibodies Market for Other Disorders
17.3.15.3.2. Proteins Market for Other Disorders
17.3.15.3.3. Peptides Market for Other Disorders
17.3.15.3.4. Small Molecules Market for Other Disorders
17.3.15.4. Prefilled Syringes Market for Other Disorders: Analysis by Geography
17.3.15.4.1. North America Market for Other Disorders
17.3.15.4.2. Europe Market for Other Disorders
17.3.15.4.3. Asia Pacific Market for Other Disorders
17.3.15.4.4. Latin America Market for Other Disorders
17.3.15.4.5. Middle East and Africa Market for Other Disorders

18. KEY GROWTH DRIVERS
18.1. Chapter Overview
18.2. Rising Incidence of Chronic Diseases
18.3. Growing Preference for Self-Injection
18.4. Evolving Patient Demographics
18.5. Growth of Biologics and Biosimilars Market
18.6. Changing Pharmaceutical Strategies
18.7. Increasing Focus on Prevention of Needlestick Injuries
18.8. Prefilled Syringes in Autoinjectors and Pen Injectors

19. SWOT ANALYSIS
19.1. Chapter Overview
19.2. Strengths 
19.3. Weaknesses
19.4. Opportunities
19.5. Threats 
19.6. Concluding Remarks

20. PREFILLED SYRINGE COMPONENT MANUFACTURERS
20.1. Chapter Overview
20.2. List of Component Manufacturers
20.3. West Pharmaceutical
20.3.1. Company Overview
20.3.2. Financial Performance
20.3.3. Product Portfolio
20.3.4. Recent Developments and Future Outlook

20.4. Datwyler Sealing Solutions (a Part of Datwyler Group)
20.4.1. Company Overview
20.4.2. Financial Performance
20.4.3. Product Portfolio
20.4.4. Recent Developments
20.4.5 Future Outlook

20.5. Aptar Pharma (a Part of AptarGroup)
20.5.1. Company Overview
20.5.2. Financial Performance
20.5.3. Product Portfolio
20.5.4. Recent Developments
20.5.5. Future Outlook

20.6. Becton Dickinson
20.6.1. Company Overview
20.6.2. Financial Information
20.6.3. Product Portfolio
20.6.4. Recent Development and Future Outlook

20.7. Ompi (a Part of Stevanato Group)
20.7.1. Company Overview
20.7.2. Product Portfolio
20.7.3. Recent Developments and Future Outlook

20.8. Lonstroff (a Part of Sumitomo Rubber Industries)
20.8.1. Company Overview
20.8.2. Financial Performance
20.8.3. Product Portfolio
20.8.4. Recent Developments
20.8.5. Future Outlook

21. FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES
21.1. Chapter Overview
21.2. Fill / Finish Processing of Prefilled Syringes
21.2.1. Steps Involved in Fill / Finish Process
21.2.2. Methods of Filling and Stoppering of Prefilled Syringes
21.2.3. Prefilled Syringe Filling Technologies

21.3. Outsourcing Fill / Finish Operations
21.4. Growth Considerations
21.5. Prefilled Syringes: List of Fill / Finish Service Providers
21.5.1. Analysis by Year of Establishment
21.5.2. Analysis by Type of Drug Molecule and Location of Headquarters 
21.5.3. Analysis by Scale of Operation 

22. CASE STUDY: AUTOINJECTORS
22.1. Chapter Overview
22.2. Market Overview of Autoinjectors

22.3. Key Players
22.3.1. Elcam Medical (E3D Elcam Drug Delivery Devices)
22.3.1.1. Company Overview
22.3.1.2. Product Portfolio

22.3.2. Nuance Designs
22.3.2.1. Company Overview
22.3.2.2. Product Portfolio

22.3.3. Owen Mumford
22.3.3.1. Company Overview
22.3.3.2. Product Portfolio

22.3.4. Scandinavian Health Limited (SHL) Group
22.3.4.1. Company Overview
22.3.4.2. Product Portfolio

22.3.5. Union Medico
22.3.5.1. Company Overview
22.3.5.2. Product Portfolio

22.3.6. Ypsomed 
22.3.6.1. Company Overview
22.3.6.2. Product Portfolio

23. CONCLUDING REMARKS
23.1. Chapter Overview
23.2. Key Takeaways

24. INTERVIEW TRANSCRIPTS
24.1. Chapter Overview
24.2. Oval Medical Technologies
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Matthew Young, Founder and Chief Technology Officer

24.3. Intas Pharmaceuticals
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Kirti Maheshwari, Chief Operating Officer

24.4. IDT Biologika
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Gregor Kawaletz, Ex-Chief Commercial Officer

24.5. West Pharmaceutical
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Tibor Hlobik, Senior Director, Product Technology Services and Kevin Cancelliere, Ex-Director, Pharmaceutical Delivery Systems Marketing

24.6. Lonstroff 
24.6.1. Company Snapshot
24.6.2. Interview Transcript: Marco Pederiva, Head of R&D and Product Strategy

24.7. IDEO 
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Jesse Fourt, Design Directors

24.8. Small-sized Medical Device Company
24.8.1. Interview Transcript: Anonymous, Chief Executive Officer

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES

List Of Figures

Figure 3.1 Glass Barrel Prefilled Syringes: Advantages and Disadvantages
Figure 3.2 Plastic Barrel Prefilled Syringes: Advantages and Disadvantages
Figure 3.3 Critical Design Parameters of Prefilled Syringes
Figure 3.4 Prefilled Syringe Manufacturing: Processes Involved
Figure 4.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Figure 4.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 4.3 Prefilled Syringes: Distribution by Type of Needle System
Figure 4.4 Prefilled Syringes: Distribution by Device Capacity
Figure 4.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Figure 4.6 Prefilled Syringe Developers: Distribution by Company Size
Figure 4.7 Prefilled Syringe Developers: Distribution by Location of Headquarters
Figure 4.8 Prefilled Syringe Developers: Distribution by Company Size and Location of Headquarters
Figure 4.9 Prefilled Syringe Developers: Distribution by Location of Manufacturing Facilities
Figure 4.10 Technological Evolution of Prefilled Syringes
Figure 5.1 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 5.2 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 6.1 BD Medical: Annual Revenues, 2013 - 2021 (USD Billion)
Figure 6.2 BD Medical: Distribution of Revenues by Business Segments (2021)
Figure 6.3 Pfizer Hospital: Annual Revenues, 2011 - 2021 (USD Million)
Figure 6.4 West Pharmaceutical: Annual Revenue, 2013 – 9M 2021 (USD Million)
Figure 6.5 West Pharmaceutical: Distribution of Revenues by Business Segments, 2020
Figure 6.6 West Pharmaceutical: Distribution of Revenues by Region, 2020
Figure 6.7 Gerresheimer: Annual Revenues, 2013 - 2021 (EUR Million)
Figure 6.8 Gerresheimer: Distribution of Revenues by Business Divisions (2020)
Figure 6.9 Gerresheimer: Distribution of Revenue by Region (2020)
Figure 6.10 Stevanato Group: Annual Revenues, 2018-2021 (EUR Million)
Figure 6.11 Stevanato Group: Distribution of Revenues by Business Segments (2020)
Figure 6.12 Stevanato Group: Distribution of Revenue by Region (2020)
Figure 6.13 Schott: Annual Revenues, 2013–2021 (JPY Billion)
Figure 6.14 Schott: Distribution of Revenues by Business Segments (2020)
Figure 6.15 Schott: Distribution of Revenues by Region, (2020)
Figure 6.16 Nipro: Annual Revenue, 2013-2021 (JPY Billion)
Figure 6.17 Nipro: Distribution of Revenue by Business Segment (2020)
Figure 6.18 Nipro: Distribution of Revenue by Region (2020)
Figure 6.19 Terumo: Annual Revenues, 2012 - 9M 2021 (JPY Billion)
Figure 6.20 Terumo: Distribution of Revenues by Business Divisions (2020)
Figure 6.21 Terumo: Distribution of Revenue by Region (2020)
Figure 6.22 Weigao: Annual Revenues, 2014 - 6M 2021 (RMB Billion)
Figure 6.23 Weigao: Distribution of Revenue by Principle Products (2020)
Figure 6.24 Weigao: Distribution of Revenue by Region (2020)
Figure 7.1 Worldwide Evolution in Healthcare Safety Legislation
Figure 8.1 Global Regulations Related to Prefilled Syringes
Figure 8.2 Approval Pathway for Combination Products in the US
Figure 8.3 Approval Pathway for Combination Products in Canada
Figure 8.4 Pharmaceuticals and Medical Devices Agency: Review / Approval Process
Figure 8.5 Approval Pathway for Combination Products in China
Figure 9.1 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Figure 9.2 Approved Prefilled Syringe Combination Products: Distribution by Year
Figure 9.3 Approved Prefilled Syringe Combination Products: Distribution by Geography
Figure 9.4 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Figure 9.5 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Figure 9.6 Approved Prefilled Syringe Combination Products: Distribution by Other Dosage Forms
Figure 9.7 Clinical Stage Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Figure 9.8 Clinical Stage Prefilled Syringe Combination Products: Distribution by Phase of Development
Figure 9.9 Clinical Stage Prefilled Syringe Combination Products: Distribution by Route of Administration
Figure 9.10 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Figure 9.11 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Figure 9.12 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Figure 9.13 Prefilled Syringe Combination Product Developers: Distribution by Location of Headquarters
Figure 9.14 Sales of Leading Drugs Available in Prefilled Syringes, 2021 (USD Billion)
Figure 9.15 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 9.16 HUMIRA®: Approval Timeline for Different Dosage Forms (US and EU)
Figure 9.17 HUMIRA®: Annual Sales, 2003-9M 2021 (USD Million)
Figure 9.18 Enbrel®: Approval Timeline (US and EU)
Figure 9.19 Enbrel®: Approval Timeline for Different Dosage Forms (US and EU)
Figure 9.20 Enbrel®: Annual Sales in the US and Canada, 2002-2021 (USD Million)
Figure 9.21 Enbrel®: Annual Sales in other regions, 2010-2021 (USD Million)
Figure 9.22 Enbrel®: Annual Sales in the US and Canada, 2002-2021 (USD Million)
Figure 9.23 Enbrel®: Annual Sales in other regions, 2010-2021 (USD Million)
Figure 11.1 Most Likely Partners for Prefilled Syringe Combination Product Developers in North America
Figure 11.2 Likely Partners for Prefilled Syringe Combination Product Developers in North America
Figure 11.3 Less Likely Partners for Prefilled Syringe Combination Product Developers in North America
Figure 11.4 Least Likely Partners for Prefilled Syringe Combination Product Developers in North America
Figure 11.5 Most Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Figure 11.6 Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Figure 11.7 Less Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Figure 11.8 Least Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Figure 11.9 Most Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Figure 11.10 Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Figure 11.11 Less Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Figure 11.12 Least Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Figure 12.1 Big Pharma Initiatives: Distribution by Therapeutic Area
Figure 12.2 Big Pharma Initiatives for Autoimmune Disorders
Figure 12.3 Big Pharma Initiatives for Autoimmune Disorders: Distribution by Target Indication
Figure 12.4 Big Pharma Initiatives for Infectious Diseases
Figure 12.5 Big Pharma Initiatives for Infectious Diseases: Distribution by Target Indication
Figure 12.6 Big Pharma Initiatives for Oncological Disorders
Figure 12.7 Big Pharma Initiatives for Oncological Disorders: Distribution by Target Indication
Figure 12.8 Big Pharma Initiatives for Metabolic Disorders
Figure 12.9 Big Pharma Initiatives for Metabolic Disorders: Distribution by Target Indication
Figure 12.10 Big Pharma Initiatives for Neurological Disorders
Figure 12.11 Big Pharma Initiatives for Neurological Disorders: Distribution by Target Indication
Figure 12.12 Big Pharma Initiatives for Inflammatory Disorders
Figure 12.13 Big Pharma Initiatives for Inflammatory Disorders: Distribution by Target Indication
Figure 12.14 Big Pharma Initiatives for Orthopedic Disorders
Figure 12.15 Big Pharma Initiatives for Orthopedic Disorders: Distribution by Target Indication
Figure 12.16 Big Pharma Initiatives for Cardiovascular Disorders
Figure 12.17 Big Pharma Initiatives for Cardiovascular Disorders: Distribution by Target Indication
Figure 12.18 Big Pharma Initiatives for Respiratory Disorders
Figure 12.19 Big Pharma Initiatives for Respiratory Disorders: Distribution by Target Indication
Figure 12.20 Big Pharma Initiatives for Ophthalmic Disorders
Figure 12.21 Big Pharma Initiatives for Ophthalmic Disorders: Distribution by Target Indication
Figure 12.22 Big Pharma Initiatives for Other Disorders
Figure 12.23 Big Pharma Initiatives: Distribution by Type of Drug Molecule
Figure 12.24 Big Pharma Initiatives: Distribution by Antibodies
Figure 12.25 Big Pharma Initiatives: Distribution by Vaccines
Figure 12.26 Big Pharma Initiatives: Distribution by Proteins
Figure 12.27 Big Pharma Initiatives: Distribution by Small Molecules
Figure 12.28 Big Pharma Initiatives: Distribution by Peptides
Figure 12.29 Big Pharma Initiatives: Distribution by Others
Figure 13.1 Recent Developments: Distribution by Year of Initiative
Figure 13.2 Recent Developments: Distribution by Type of Initiative
Figure 13.3 Recent Developments: Distribution by Year and Type of Initiative
Figure 13.4 Recent Developments: Distribution by Type of Expansion
Figure 13.5 Recent Developments: Distribution by Region of Expansion
Figure 13.6 Recent Developments: Distribution by Type of Partnership
Figure 13.7 Recent Developments: Distribution by Location of Headquarters
Figure 13.8 Most Active Players: Distribution by Number of Initiatives
Figure 13.9 Recent Developments: Distribution of Players by Type of Initiative
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Cumulative Distribution by Publication Year, 2017-2021
Figure 14.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 14.4 Patent Analysis: Distribution by Geography
Figure 14.5 Patent Analysis: North America Scenario
Figure 14.6 Patent Analysis: Asia-Pacific Scenario
Figure 14.7 Patent Analysis: Distribution by CPC Symbols
Figure 14.8 Patent Analysis: Distribution by Emerging Focus Area
Figure 14.9 Most Active Players: Distribution by Number of Patents
Figure 14.10 Key Inventors: Distribution by Number of Patents
Figure 14.11 Patent Benchmarking Analysis: Terumo and Sumitomo Rubber
Figure 14.12 Patent Benchmarking Analysis: Other Leading Players
Figure 14.13 Patent Portfolio: Distribution by Patent Age
Figure 14.14 Patent Valuation Analysis
Figure 14.15 Overall Intellectual Property Portfolio: Distribution by Type of Organization
Figure 17.1 Cost of Prefilled Syringes: Conservative, Base and Optimistic Scenarios, 2022-2035 (USD)
Figure 17.2 Global Prefilled Syringes Market, 2022-2035 (Million Unit)
Figure 17.3 Global Prefilled Syringes Market, 2022-2035 (USD Million)
Figure 17.4 Prefilled Syringes Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 17.5 Prefilled Syringes Market: Share of Autoimmune Disorders, 2022-2035 (USD Million)
Figure 17.6 Prefilled Syringes Market: Share of Infectious Diseases, 2022-2035 (USD Million)
Figure 17.7 Prefilled Syringes Market: Share of Neurological Disorders, 2022-2035 (USD Million)
Figure 17.8 Prefilled Syringes Market: Share of Blood Disorders, 2022-2035 (USD Million)
Figure 17.9 Prefilled Syringes Market: Share of Oncological Disorders, 2022-2035 (USD Million)
Figure 17.10 Prefilled Syringes Market: Share of Respiratory Disorders, 2022-2035 (USD Million)
Figure 17.11 Prefilled Syringes Market: Share of Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 17.12 Prefilled Syringes Market: Share of Metabolic Disorders, 2022-2035 (USD Million)
Figure 17.13 Prefilled Syringes Market: Share of Ophthalmic Disorder, 2022-2035 (USD Million)
Figure 17.14 Prefilled Syringes Market: Share of Orthopedic Disorders, 2022-2035 (USD Million)
Figure 17.15 Prefilled Syringes Market: Share of Other Diseases, 2022-2035 (USD Million)
Figure 17.16 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2022 - 2035 (USD Million)
Figure 17.17 Prefilled Syringes Market: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.18 Prefilled Syringes Market: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.19 Prefilled Syringes Market: Distribution by Type of Chamber System, 2022 - 2035 (USD Million)
Figure 17.20 Prefilled Syringes Market: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.21 Prefilled Syringes Market: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.22 Prefilled Syringes Market: Distribution by Type of Drug Molecule, 2022-2035 (USD Million)
Figure 17.23 Prefilled Syringes Market: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.24 Prefilled Syringes Market: Share of Proteins, 2022-2035 (USD Million)
Figure 17.25 Prefilled Syringes Market: Share of Peptides, 2022-2035 (USD Million)
Figure 17.26 Prefilled Syringes Market: Share of Small Molecules, 2022-2035 (USD Million)
Figure 17.27 Prefilled Syringes Market: Share of Vaccines, 2022-2035 (USD Million)
Figure 17.28 Prefilled Syringes Market: Distribution by Geography
Figure 17.29 Prefilled Syringes Market: Share of North America, 2022-2035 (USD Million)
Figure 17.30 Prefilled Syringes Market: Share of Europe, 2022-2035 (USD Million)
Figure 17.31 Prefilled Syringes Market: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.32 Prefilled Syringes Market: Share of Latin America, 2022-2035 (USD Million)
Figure 17.33 Prefilled Syringes Market: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.34 Prefilled Syringes Market: Distribution by Specialty Syringes, 2022-2035 (USD Million)
Figure 17.35 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.36 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.37 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.38 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.39 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.40 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, 2022-2035 (USD Million)
Figure 17.41 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.42 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.43 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.44 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.45 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.46 Prefilled Syringes Market for Infectious Diseases: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.47 Prefilled Syringes Market for Infectious Diseases: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.48 Prefilled Syringes Market for Infectious Diseases: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.49 Prefilled Syringes Market for Infectious Diseases: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.50 Prefilled Syringes Market for Infectious Diseases: Share of Vaccines, 2022-2035 (USD Million)
Figure 17.51 Prefilled Syringes Market for Infectious Diseases: Share of North America, 2022-2035 (USD Million)
Figure 17.52 Prefilled Syringes Market for Infectious Diseases: Share of Europe, 2022-2035 (USD Million)
Figure 17.53 Prefilled Syringes Market for Infectious Diseases: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.54 Prefilled Syringes Market for Infectious Diseases: Share of Latin America, 2022-2035 (USD Million)
Figure 17.55 Prefilled Syringes Market for Infectious Diseases: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.56 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.57 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.58 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.59 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.60 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.61 Prefilled Syringes Market for Neurological Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.62 Prefilled Syringes Market for Neurological Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.63 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.64 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.65 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.66 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.67 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.68 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.69 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.70 Prefilled Syringes Market for Blood Disorders: Share of Proteins, 2022-2035 (USD Million)
Figure 17.71 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, 2022-2035 (USD Million)
Figure 17.72 Prefilled Syringes Market for Blood Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.73 Prefilled Syringes Market for Blood Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.74 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.75 Prefilled Syringes Market for Blood Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.76 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.77 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.78 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.79 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.80 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.81 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.82 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, 2022-2035 (USD Million)
Figure 17.83 Prefilled Syringes Market for Oncological Disorders: Share of Peptides, 2022-2035 (USD Million)
Figure 17.84 Prefilled Syringes Market for Oncological Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.85 Prefilled Syringes Market for Oncological Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.86 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.87 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.88 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.89 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.90 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.91 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.92 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.93 Prefilled Syringes Market for Metabolic Disorders: Share of Peptides, 2022-2035 (USD Million)
Figure 17.94 Prefilled Syringes Market for Metabolic Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.95 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.96 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.97 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.98 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.99 Prefilled Syringes Market for Respiratory Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.100 Prefilled Syringes Market for Respiratory Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.101 Prefilled Syringes Market for Respiratory Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.102 Prefilled Syringes Market for Respiratory Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.103 Prefilled Syringes Market for Respiratory Disorders: Share of Peptides, 2022-2035 (USD Million)
Figure 17.104 Prefilled Syringes Market for Respiratory Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.105 Prefilled Syringes Market for Respiratory Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.106 Prefilled Syringes Market for Respiratory Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.107 Prefilled Syringes Market for Respiratory Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.108 Prefilled Syringes Market for Respiratory Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.109 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.110 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.111 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.112 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.113 Prefilled Syringes Market for Metabolic Disorders: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.114 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, 2022-2035 (USD Million)
Figure 17.115 Prefilled Syringes Market for Metabolic Disorders: Share of Small Molecules, 2022-2035 (USD Million)
Figure 17.116 Prefilled Syringes Market for Metabolic Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.117 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.118 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.119 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.120 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.121 Prefilled Syringes Market for Cardiovascular Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.122 Prefilled Syringes Market for Cardiovascular Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.123 Prefilled Syringes Market for Cardiovascular Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.124 Prefilled Syringes Market for Cardiovascular Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.125 Prefilled Syringes Market for Cardiovascular Disorders: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.126 Prefilled Syringes Market for Cardiovascular Disorders: Share of Peptide, 2022-2035 (USD Million)
Figure 17.127 Prefilled Syringes Market for Cardiovascular Disorders: Share of Small Molecules, 2022-2035 (USD Million)
Figure 17.128 Prefilled Syringes Market for Cardiovascular Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.129 Prefilled Syringes Market for Cardiovascular Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.130 Prefilled Syringes Market for Cardiovascular Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.131 Prefilled Syringes Market for Cardiovascular Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.132 Prefilled Syringes Market for Cardiovascular Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 17.133 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Syringes, 2022-2035 (USD Million)
Figure 17.134 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Syringes, 2022-2035 (USD Million)
Figure 17.135 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Syringes, 2022-2035 (USD Million)
Figure 17.136 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Syringes, 2022-2035 (USD Million)
Figure 17.137 Prefilled Syringes Market for Other Disorders: Share of Antibodies, 2022-2035 (USD Million)
Figure 17.138 Prefilled Syringes Market for Other Disorders: Share of Peptide, 2022-2035 (USD Million)
Figure 17.139 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, 2022-2035 (USD Million)
Figure 17.140 Prefilled Syringes Market for Other Disorders: Share of North America, 2022-2035 (USD Million)
Figure 17.141 Prefilled Syringes Market for Other Disorders: Share of Europe, 2022-2035 (USD Million)
Figure 17.142 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, 2022-2035 (USD Million)
Figure 17.143 Prefilled Syringes Market for Other Disorders: Share of Latin America, 2022-2035 (USD Million)
Figure 17.144 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, 2022-2035 (USD Million)
Figure 18.1 Diabetes: Country Wise Distribution of Prevalence and Mortality, 2017
Figure 18.2 FDA Approved Biologics, 2009-2021
Figure 18.3 Top Selling Biologics: Estimated Patent Expiry
Figure 19.1 SWOT Analysis: Overview
Figure 19.2 Prefilled Syringe Recalls: Distribution by Type of Error, 2003-2019
Figure 19.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 20.1 Datwyler Group: Annual Revenues, 2013–2021 (CHF Billion)
Figure 20.2 Aptar Pharma: Annual Revenues, 2013-H1 2019 (USD Billion)
Figure 20.3 Sumitomo Rubber Industries: Annual Revenue, 2013–9M 2021(JPY Billion)
Figure 20.4 Sumitomo Rubber Industries: Distribution of Revenues by Business Segments, (2020)
Figure 21.1 Prefilled Syringe: Fill / Finish Process
Figure 21.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 21.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 21.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Location of Headquarters and Type of Drug Molecule
Figure 22.1 Elcam Medical: Product Portfolio
Figure 22.2 Elcam Medical: Flexi-Q Autoinjectors
Figure 22.3 Flexi-Q PFS: Key Components
Figure 22.4 Flexi-Q PFS: Mechanism of Drug Delivery
Figure 22.5 Flexi-Q DV: Key Components
Figure 22.6 Flexi-Q DV: Mechanism of Drug Delivery
Figure 22.7 Flexi-Q mMU: Key Components
Figure 22.8 Flexi-Q eMU: Key Components
Figure 22.9 Flexi-Q mMU / Flexi-Q eMU: Mechanism of Drug Delivery
Figure 22.10 Flexi-Q EAI: Mechanism of Drug Delivery
Figure 22.11 Owen Mumford: Product Portfolio
Figure 22.12 Autoject Micro: Mechanism of Drug Delivery
Figure 22.13 Autoject 2 Autoinjector: Mechanism of Drug Delivery
Figure 22.14 Autoject Mini: Mechanism of Drug Delivery
Figure 22.15 SHL Medical: Product Portfolio
Figure 22.16 SHL Medical: Prefilled Syringe-based Autoinjectors
Figure 22.17 SHL Medical: Cartridge-based Autoinjectors
Figure 22.18 SHL Medical: Two-Step Autoinjectors
Figure 22.19 SHL Medical Two-Step Autoinjectors: Mechanism of Drug Delivery
Figure 22.20 Union Medico: 45? Autoinjector Portfolio
Figure 22.21 Union Medico: Parts of 45?/ R Autoinjector
Figure 22.22 Union Medico: Types of 45?/ R Autoinjector
Figure 22.23 Union Medico: Types of 90? Autoinjectors
Figure 22.24 Key Components of Autoinjectors
Figure 22.25 Ypsomed: Annual Revenues, 2015- 2021 (CHF Million)
Figure 22.26 Ypsomed: Sales by Business Divisions, 20XX (CHF Million, %)
Figure 22.27 Ypsomed: Product Portfolio
Figure 22.28 YpsoMate: Mechanism of Drug Delivery
Figure 22.29 VarioJect: Mechanism of Drug Delivery

List Of Tables

Table 3.1 List of Drugs: Migration From Vials to Prefilled Syringe Format
Table 3.2 Components of Prefilled Syringes
Table 3.3 Classification of Prefilled Syringes
Table 3.4 Advantages of Glass Barrel Fabrication Material
Table 3.5 Glass Barrel Prefilled Syringe Recalls
Table 3.6 Advantages of Plastic Polymer Barrel Fabrication Material
Table 3.7 Steps Involved in Filling Process for Prefilled Syringe
Table 4.1 Prefilled Syringes: List of Available / Under Development Devices
Table 4.2 Prefilled Syringes: List of Developers
Table 6.1 Key Manufacturers of Prefilled Syringes
Table 6.2 Becton Dickinson: Future Outlook
Table 6.3 West Pharmaceutical: Features of Daikyo Crystal Zenith Prefilled Syringe
Table 6.4 West Pharmaceutical: Future Outlook
Table 6.5 Gerresheimer: Features of Gx Glass Prefilled Syringe
Table 6.6 Gerresheimer: Features of ClearJect Prefilled Syringe
Table 6.7 Gerresheimer: Features of Gx RTF ClearJect Prefilled Syringe
Table 6.8 Gerresheimer: Future Outlook
Table 6.9 Ompi: Features of EZ-Fill Fina Prefilled Syringe
Table 6.10 Ompi: Features of EZ-Fill Nexa Prefilled Syringe
Table 6.11 Ompi: Features of EZ-Fill Alba Prefilled Syringe
Table 6.12 Ompi: Future Outlook
Table 6.13 Schott: Features of syriQ Prefilled Syringe
Table 6.14 Schott: Features of TopPac Prefilled Syringe
Table 6.15 Schott: Future Outlook
Table 6.16 Nipro: Features of Prefilled Syringe
Table 6.17 Taisei Kako: Features of VF-Syringes
Table 6.18 Taisei Kako: Features of SIN-Syringes
Table 6.19 Taisei Kako: Features of ClearJect Prefilled Syringes
Table 6.20 Taisei Kako: Features of FULJECT Passive Type Syringes
Table 6.21 Shandong Zibo: Features of Prefilled Syringes
Table 6.22 Terumo: Features of Plajex Syringes
Table 6.23 Terumo: Future Outlook
Table 6.24 Vetter Pharma: Features of Lyo-Ject Glass Prefilled Syringe
Table 6.25 Weigao: Features of WeGo Glass Prefilled Syringe
Table 7.1 Add-On Safety Device Manufacturers
Table 7.2 Integrated Prefilled Safety Device Manufacturers
Table 8.1 US FDA Center for Drug and Device Approval
Table 8.2 Regulatory Review Timelines in the US
Table 8.3 Regulatory Bodies in EU5 Countries
Table 8.4 Regulatory Device classification in Japan
Table 8.5 Regulatory Review Timelines in Saudi Arabia
Table 9.1 Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2021
Table 9.2 Prefilled Syringe Combination Products: Information on Approval Year and Key Geographies, 2013-2021
Table 9.3 Prefilled Syringe Combination Products: Information on Dosage Strength
Table 9.4 Prefilled Syringe Combination Products: List of Other Drug Delivery Solutions, 2013-2021
Table 9.5 Prefilled Syringe Combination Products: List of Clinical Stage Drugs, 2013-2021
Table 9.6 Prefilled Syringe Combination Products: List of Developers
Table 9.7 Other Drugs Sold in Prefilled Syringes
Table 10.1 List of Leading Drugs Approved for Autoimmune Disorders
Table 10.2 List of Leading Drugs Available in Prefilled Syringes for Autoimmune Disorders
Table 10.3 Information on Patent Expiry and Biosimilar Development Initiatives for Drugs Approved for Delivery via Prefilled Syringes for Autoimmune Disorders
Table 10.4 List of Leading Drugs Approved for Antiviral Disorders
Table 10.5 List of Leading Drugs Available in Prefilled Syringes Antiviral Drugs
Table 10.6 Information on Patent Expiry and Biosimilar Development Initiatives for Drugs Approved for Delivery via Prefilled Syringes for Infectious Diseases
Table 10.7 List of Leading Drugs Approved for Infectious Disorders
Table 10.8 List of Leading Drugs Available in Prefilled Syringes for Infectious Disorders
Table 10.9 List of Leading Drugs Approved for Neurological Disorders
Table 10.10 List of Leading Drugs Available in Prefilled Syringes for Neurological Disorders
Table 10.11 Information on Patent Expiry and Biosimilar Development Initiatives for Drugs Approved for Delivery via Prefilled Syringes for Neurological Disorders
Table 10.12 List of Leading Drugs Approved for Metabolic Disorders
Table 10.13 List of Leading Drugs Available in Prefilled Insulin Prefilled Syringes / Pen
Table 10.14 Information on Patent Expiry and Biosimilar Development Initiatives for Drugs Approved for Delivery via Prefilled Syringes for Metabolic Disorders
Table 11.1 Most Likely Marketed Drugs for Delivery via Prefilled Syringes
Table 11.2 Likely Candidates Marketed Drugs for Delivery via Prefilled Syringes
Table 11.3 Less Likely Candidates Marketed Drugs for Delivery via Prefilled Syringes
Table 11.4 Least Likely Candidates Marketed Drugs for Delivery via Prefilled Syringes
Table 11.5 Most Likely Clinical Stage Drug Candidates for Delivery via Prefilled Syringes
Table 11.6 Likely Clinical Stage Drug Candidates for Delivery via Prefilled Syringes
Table 11.7 Less Likely Clinical Stage Drug Candidates for Delivery via Prefilled Syringes
Table 11.8 Least Likely Clinical Stage Drug Candidates for Delivery via Prefilled Syringes
Table 13.1 Recent Developments: List of Initiatives, 2019 – 2021
Table 14.1 Patent Analysis: List of Top CPC Symbols
Table 14.2 Patent Analysis: Summary of Benchmarking Analysis
Table 14.3 Patent Analysis: Various Categorizations based on Weighted Valuation Scores
Table 14.4 Patent Analysis: List of Leading Patents (In Terms of Highest Relative Valuation)
Table 15.1 Prefilled Flush Syringes Available in the Market
Table 15.2 Drugs Available with Prefilled Diluent Syringe Systems
Table 15.3 Contrast Agents Available in Prefilled Syringes
Table 16.1 List of Dual / Multi-Chamber Prefilled Syringes
Table 16.2 List of Drugs Marketed in Dual / Multi-Chamber Prefilled Syringes
Table 16.3 Therapeutic Areas: Relative Share of Approved and Clinical Products with Prefilled Syringes
Table 18.1 Fraction of Global Population above 60 years (in Millions), 2022, 2030 and 2050
Table 18.2 Autoinjector Approvals, 2016-2021
Table 18.3 List of Marketed Autoinjectors / Pen Injectors Available in Prefilled Syringe Format
Table 19.1 List of Marketed/Pipeline Needleless Injection Devices
Table 19.2 List of Prefilled Syringe Recalls, 2003-2021
Table 20.1 Prefilled Syringe Component Manufacturers: List of Elastomeric Component Providers
Table 20.2 Prefilled Syringes Elastomeric Container Closure Providers: List of Companies Profiled
Table 20.3 West Pharmaceuticals: Company Overview
Table 20.4 West Pharmaceuticals: Product Portfolio
Table 20.5 Datwyler Sealing Solutions (Datwyler Group): Company Overview
Table 20.6 Datwyler Sealing Solutions (Datwyler Group): Product Portfolio
Table 20.7 Datwyler Sealing Solutions (Datwyler Group): Recent Developments and Future Outlook
Table 20.8 Becton Dickinson: Company Overview
Table 20.9 Becton Dickinson: Product Portfolio
Table 20.10 Ompi: Company Overview
Table 20.11 Ompi: Product Portfolio
Table 20.12 Lonstroff: Company Overview
Table 20.13 Sumitomo Rubber Industries: Company Overview
Table 20.14 Lonstroff: Product Portfolio
Table 21.1 List of Fill / Finish Service Providers
Table 21.2 List of Autoinjector Devices (Using Prefilled Syringes)
Table 21.3 YpsoMate Autoinjectors: Dimensions of Prefilled Syringes
Table 21.4 Prefilled Syringes Market: Key Takeaways
Table 23.1 Oval Medical Technologies: Key Highlights
Table 23.2 Intas Pharmaceuticals: Key Highlights
Table 23.3 IDT Biologika: Key Highlights
Table 23.4 West Pharmaceutical: Key Highlights
Table 23.5 Lonstroff: Key Highlights
Table 24.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 24.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 24.3 Prefilled Syringes: Distribution by Type of Needle System
Table 24.4 Prefilled Syringes: Distribution by Packing Volume of Syringe
Table 24.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Table 24.6 Prefilled Syringe Developers: Distribution by Company Size
Table 24.7 Prefilled Syringe Developers: Distribution by Location of Headquarters
Table 24.8 Prefilled Syringe Developers: Distribution by Company Size and Location of Headquarters
Table 24.9 Prefilled Syringe Developers: Distribution by Location of Manufacturing Facilities
Table 24.11 BD Medical: Annual Revenues, 2013 - 2021 (USD Billion)
Table 24.12 BD Medical: Distribution of Revenue by Business Segments (2021)
Table 24.13 Pfizer Hospital: Annual Revenues, 2011 - 2021 (USD Million)
Table 24.14 West Pharmaceutical: Annual Revenue, 2013 – 9M 2021 (USD Million)
Table 24.15 West Pharmaceutical: Distribution of Revenue by Business Segments, 2020
Table 24.16 West Pharmaceutical: Distribution of Revenue by Region, 2020
Table 24.17 Gerresheimer: Annual Revenues, 2013 - 2021 (EUR Million)
Table 24.18 Gerresheimer: Distribution of Revenue by Business Divisions (2020)
Table 24.19 Gerresheimer: Distribution of Revenue by Region (2020)
Table 24.20 Stevanato Group: Annual Revenues, 2018-2021 (EUR Million)
Table 24.21 Stevanato Group: Distribution of Revenue by Business Segments (2020)
Table 24.22 Stevanato Group: Distribution of Revenue by Region (2020)
Table 24.23 Schott: Annual Revenues, 2013–2021 (JPY Billion)
Table 24.24 Schott: Distribution of Revenues by Business Segment (2020)
Table 24.25 Schott: Distribution of Revenues by Region, (2020)
Table 24.26 Nipro: Annual Revenue, 2013-2021 (JPY Billion)
Table 24.27 Nipro: Distribution of Revenue by Business Segment (2020)
Table 24.28 Nipro: Distribution of Revenue by Region (2020)
Table 24.29 Terumo: Annual Revenues, 2012 - 9M 2021 (JPY Billion)
Table 24.30 Terumo: Distribution of Revenue by Business Divisions (2020)
Table 24.31 Terumo: Distribution of Revenue by Region (2020)
Table 24.32 Weigao: Annual Revenues, 2014 - 6M 2021 (RMB Billion)
Table 24.33 Weigao: Distribution of Revenue by Principle Products (2020)
Table 24.34 Weigao: Distribution of Revenue by Region (2020)
Table 24.35 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Table 24.36 Approved Prefilled Syringe Combination Products: Distribution by Year
Table 24.37 Approved Prefilled Syringe Combination Products: Distribution by Geography
Table 24.38 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Table 24.39 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Table 24.40 Approved Prefilled Syringe Combination Products: Distribution by Other Dosage Forms
Table 24.41 Clinical Stage Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Table 24.42 Clinical Stage Prefilled Syringe Combination Products: Distribution by Phase of Development
Table 24.43 Clinical Stage Prefilled Syringe Combination Products: Distribution by Route of Administration
Table 24.44 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Table 24.45 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Table 24.46 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Table 24.47 Prefilled Syringe Combination Product Developers: Distribution by Location of Headquarters
Table 24.48 Sales of Leading Drugs Available in Prefilled Syringes, 2021 (USD Billion)
Table 24.49 HUMIRA®: Annual Sales, 2003 – 9M 2021(USD Million)
Table 24.50 Enbrel®: Annual Sales in the US and Canada, 2002-2021(USD Million)
Table 24.51 Enbrel®: Annual Sales in Other regions, 2010-2021 (USD Million)
Table 24.52 Enbrel®: Annual Sales in the US and Canada, 2002-2021 (USD Million)
Table 24.53 Enbrel®: Annual Sales in other regions, 2010-2021 (USD Million)
Table 24.54 Most Likely Partners for Prefilled Syringe Combination Product Developers in North America
Table 24.55 Likely Partners for Prefilled Syringe Combination Product Developers in North America
Table 24.56 Less Likely Partners for Prefilled Syringe Combination Product Developers in North America
Table 24.57 Least Likely Partners for Prefilled Syringe Combination Product Developers in North America
Table 24.58 Most Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Table 24.59 Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Table 24.60 Less Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Table 24.61 Least Likely Partners for Prefilled Syringe Combination Product Developers in Europe
Table 24.62 Most Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Table 24.63 Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Table 24.64 Less Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Table 24.65 Least Likely Partners for Prefilled Syringe Combination Product Developers in Asia-Pacific and RoW
Table 24.66 Recent Developments: Distribution by Year of Initiative
Table 24.67 Recent Developments: Distribution by Type of Initiative
Table 24.68 Recent Developments: Distribution by Year and Type of Initiative
Table 24.69 Recent Developments: Distribution by Type of Expansions
Table 24.70 Recent Developments: Distribution by Region of Expansion
Table 24.71 Recent Developments: Distribution by Focus of Expansion
Table 24.72 Recent Developments: Distribution by Type of Partnership
Table 24.73 Recent Developments: Distribution by Location of Headquarters
Table 24.74 Most Active Players: Distribution by Number of Initiatives
Table 24.75 Patent Analysis: Distribution by Type of Patent
Table 24.76 Patent Analysis: Cumulative Distribution by Publication Year, 2017-2021
Table 24.77 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 24.78 Patent Analysis: Distribution by Geography
Table 24.79 Patent Analysis: North America Scenario
Table 24.80 Patent Analysis: Europe Scenario
Table 24.81 Patent Analysis: Asia-Pacific Scenario
Table 24.82 Most Active Players: Distribution by Number of Patents
Table 24.83 Key Inventors: Distribution by Number of Patents
Table 24.84 Overall Intellectual Property Portfolio: Distribution by Type of Organization
Table 24.85 Patent Portfolio: Distribution by Patent Age
Table 24.86 Cost of Prefilled Syringes: Conservative, Base and Optimistic Scenarios, 2022-2035 (USD)
Table 24.87 Global Prefilled Syringes Market, 2022-2035 (Million Unit)
Table 24.88 Global Prefilled Syringes Market, 2022-2035 Conservative, Base and Optimistic Scenarios, (USD Million)
Table 24.89 Prefilled Syringes Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 24.90 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.91 Prefilled Syringes Market: Share of Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.92 Prefilled Syringes Market: Share of Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.93 Prefilled Syringes Market: Share of Blood Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.94 Prefilled Syringes Market: Share of Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.95 Prefilled Syringes Market: Share of Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.96 Prefilled Syringes Market: Share of Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.97 Prefilled Syringes Market: Share of Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.98 Prefilled Syringes Market: Share of Ophthalmic Disorder, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.99 Prefilled Syringes Market: Share of Orthopedic Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.100 Prefilled Syringes Market: Share of Other Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.101 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2022 – 2035 (USD Million)
Table 24.102 Prefilled Syringes Market: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.103 Prefilled Syringes Market: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.104 Prefilled Syringes Market: Distribution by Type of Chamber System, 2022-2035 (USD Million) (USD Million)
Table 24.105 Prefilled Syringes Market: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.106 Prefilled Syringes Market: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.107 Prefilled Syringes Market: Distribution by Type of Drug Molecule, 2022-2035 (USD Million) (USD Million)
Table 24.108 Prefilled Syringes Market: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.109 Prefilled Syringes Market: Share of Proteins, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.110 Prefilled Syringes Market: Share of Peptides, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.111 Prefilled Syringes Market: Share of Small Molecules, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.112 Prefilled Syringes Market: Share of Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.113 Prefilled Syringes Market: Distribution by Geographical Regions
Table 24.114 Prefilled Syringes Market: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.115 Prefilled Syringes Market: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.116 Prefilled Syringes Market: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.117 Prefilled Syringes Market: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.118 Prefilled Syringes Market: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.119 Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.120 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.121 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.122 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.123 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.124 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.125 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.126 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.127 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.128 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.129 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.130 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.131 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.132 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.133 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.134 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.135 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.136 Prefilled Syringes Market for Infectious Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.137 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.138 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.139 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.140 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.141 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.142 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.143 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.144 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.145 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.146 Prefilled Syringes Market for Neurological Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.147 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.148 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.149 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.150 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.151 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.152 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.153 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.154 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.155 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.156 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.157 Prefilled Syringes Market for Blood Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.158 Prefilled Syringes Market for Blood Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.159 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.160 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.161 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.162 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.163 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.164 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.165 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.166 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.167 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.168 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.169 Prefilled Syringes Market for Oncological Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.170 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.171 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.172 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.173 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.174 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.175 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.176 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.177 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.178 Prefilled Syringes Market for Metabolic Disorders: Share of Peptides, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.179 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.180 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.181 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.182 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.183 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.184 Prefilled Syringes Market for Respiratory Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.185 Prefilled Syringes Market for Respiratory Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.186 Prefilled Syringes Market for Respiratory Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.187 Prefilled Syringes Market for Respiratory Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.188 Prefilled Syringes Market for Respiratory Disorders: Share of Peptides, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.189 Prefilled Syringes Market for Respiratory Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.190 Prefilled Syringes Market for Respiratory Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.191 Prefilled Syringes Market for Respiratory Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.192 Prefilled Syringes Market for Respiratory Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.193 Prefilled Syringes Market for Respiratory Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.194 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.195 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.196 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.197 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.198 Prefilled Syringes Market for Metabolic Disorders: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.199 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.200 Prefilled Syringes Market for Metabolic Disorders: Share of Small Molecules, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.201 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.202 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.203 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.204 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.205 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.206 Prefilled Syringes Market for Cardiovascular Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.207 Prefilled Syringes Market for Cardiovascular Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.208 Prefilled Syringes Market for Cardiovascular Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.209 Prefilled Syringes Market for Cardiovascular Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.210 Prefilled Syringes Market for Cardiovascular Disorders: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.211 Prefilled Syringes Market for Cardiovascular Disorders: Share of Peptide, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.212 Prefilled Syringes Market for Cardiovascular Disorders: Share of Small Molecules, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.213 Prefilled Syringes Market for Cardiovascular Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.214 Prefilled Syringes Market for Cardiovascular Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.215 Prefilled Syringes Market for Cardiovascular Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.216 Prefilled Syringes Market for Cardiovascular Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.217 Prefilled Syringes Market for Cardiovascular Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.218 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.219 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.220 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.221 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Syringes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.222 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.223 Prefilled Syringes Market for Other Disorders: Share of Peptide, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.224 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.225 Prefilled Syringes Market for Other Disorders: Share of North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.226 Prefilled Syringes Market for Other Disorders: Share of Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.227 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.228 Prefilled Syringes Market for Other Disorders: Share of Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.229 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 24.230 Diabetes: Country Wise Distribution of Prevalence and Mortality, 2017
Table 24.231 FDA Approved Biologics, 2009-20XX
Table 24.232 Top Selling Biologics: Estimated Patent Expiry
Table 24.234 Aptar Pharma: Annual Revenues, 2013 - H1 20XX (USD Billion)
Table 24.233 Datwyler Group: Annual Revenues, 2013 – 2021 (CHF Billion)
Table 24.235 Sumitomo Rubber Industries: Annual Revenue, 2013 – 9M 2021(JPY Billion)
Table 24.236 Sumitomo Rubber Industries: Distribution of Revenue by Business Segment, (2020)
Table 24.237 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
Table 24.238 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation

List Of Companies

The following companies and organizations have been mentioned in the report

  1. 89bio
  2. Abbott Laboratories
  3. AbbVie
  4. Accord Healthcare  
  5. Adamis Pharmaceuticals  
  6. Adimmune  
  7. Advance Pharmalab
  8. Aenova
  9. AEON Biopharma
  10. Ajinomoto Bio-Pharma Services
  11. Akums Drugs & Pharmaceuticals
  12. Alcami
  13. Alder BioPharmaceuticals
  14. Alexion Pharmaceuticals
  15. Alfasigma
  16. Alkermes
  17. Allakos
  18. Allergan
  19. Alvogen
  20. Alvotech
  21. Amgen
  22. Amphastar Pharmaceuticals
  23. Amryt
  24. Andes Biotechnologies
  25. AnGes
  26. Anhui Huafeng Pharmaceutical Rubber
  27. ApcinteX (Acquired by Centessa Pharmaceuticals)
  28. Apotek Produktion & Laboratorier
  29. Apotex
  30. Aptar Pharma
  31. Araclon Biotech
  32. Arecor Therapeutics
  33. argenx
  34. Arrowhead Pharmaceuticals
  35. ARTE
  36. Asarina Pharma
  37. Ascendis Pharma
  38. Ashvattha Therapeutics
  39. Aspen Pharmacare
  40. Aspire Life Sciences
  41. ASST Fatebenefratelli Sacco
  42. Astellas Pharma
  43. Astex Pharmaceuticals
  44. AstraZeneca
  45. Atlant Clinical
  46. Atridia
  47. B. Braun
  48. Baxter BioPharma Solutions
  49. Bayer
  50. Becton Dickinson
  51. Berkshire Sterile Manufacturing
  52. Beximco Pharma
  53. Bharat Biotech
  54. BIOCAD
  55. Biocon
  56. Biogen
  57. Bioinova
  58. Birgi Mefar
  59. Boehringer Ingelheim
  60. Bone Therapeutics
  61. Bristol Myers Squibb
  62. Caliway Biopharmaceuticals
  63. Camurus 
  64. CARBOGEN AMCIS
  65. Cardinal Health
  66. CardioVascular BioTherapeutics
  67. Catalent Biologics
  68. Celgene
  69. Celldex Therapeutics
  70. Celltrion Healthcare
  71. Cenexi
  72. Centrexion Therapeutics
  73. Chong Kun Dang Pharmaceutical
  74. Chugai Pharmaceutical
  75. CinnaGen
  76. Ciron
  77. Clinuvel Pharmaceuticals
  78. Coherus BioSciences
  79. Consort Medical
  80. CordenPharma
  81. Credence MedSystems
  82. CSL Behring
  83. Cumberland Pharmaceuticals
  84. Curia (formerly known as AMRI)
  85. Cutia Therapeutics
  86. Cycle Pharmaceuticals
  87. Daewoong Pharmaceutical    
  88. Daiichi Sankyo
  89. Danyang Jincheng Medical Rubber & Plastics
  90. Data Management 365
  91. Datwyler
  92. Delpharm
  93. Dicerna Pharmaceuticals
  94. Dynavax Technologies
  95. Edge Pharma
  96. Eiger BioPharmaceuticals
  97. Eisai
  98. Eli Lilly and Company
  99. Emcure Pharmaceuticals
  100. EMD Serono
  101. Emergent BioSolutions
  102. Endocard
  103. Ethypharm
  104. Eureka Forbes
  105. Eurofarma
  106. EVER Pharma
  107. Express Service Import Export
  108. Ferring Pharmaceuticals
  109. Foresee Pharmaceuticals
  110. Fresenius Kabi
  111. Fujian Shengdi Pharmaceutical
  112. Fujifilm Toyama Chemical
  113. Galaxy Pharmaceuticals
  114. GC Pharma
  115. GemVax & KAEL
  116. Genentech
  117. Generon
  118. Genmab
  119. Gerresheimer
  120. Gilead Sciences
  121. Gland Pharma
  122. GlaxoSmithKline
  123. Glenmark Pharmaceuticals
  124. Grifols Therapeutics
  125. H K Zion Industry
  126. Hanmi Pharmaceutical
  127. Harbour BioMed
  128. Healthcare Pharmaceuticals
  129. Heptares Therapeutics
  130. Heron Therapeutics
  131. Hetero Drugs
  132. HK Surgical
  133. Hoffmann-La Roche
  134. Institut Biochimique
  135. IDT Biologika
  136. IlYang Pharmaceuticals
  137. ImmuneMed
  138. ImmunityBio
  139. Inhibrx
  140. Injecto
  141. Inmunotek 
  142. Innovent Biologics
  143. Intas Pharmaceuticals
  144. Intra-Cellular Therapies
  145. Ipsen
  146. IQVIA
  147. Italfarmaco
  148. Jain Rubbers
  149. Janssen Pharmaceuticals
  150. JCR Pharmaceuticals
  151. Jiangsu HengRui Medicine
  152. Jiangsu Hualan New Pharmaceutical Material
  153. Jiangxi Qingfeng Pharmaceutical    
  154. Jiangyin Hongmeng Rubber Plastic Product
  155. Johnson & Johnson
  156. Kastle Therapeutics
  157. Kemwell Biopharma
  158. Keymed Biosciences
  159. Kiniksa Pharmaceuticals
  160. Kitasato Daiichi Sankyo Vaccine
  161. Kymab (Acquired by Sanofi)
  162. Kyowa Hakko Kirin
  163. Labcorp
  164. Laboratoire AGUETTANT
  165. Salvat Laboratories 
  166. LEO Pharma
  167. Lundbeck
  168. Luye Pharma Group
  169. Lyophilization Services of New England (LSNE)
  170. Mapi Pharma
  171. Maruishi Pharmaceutical
  172. Medicago
  173. Medicalchain
  174. Medline
  175. Medica Scientia Innovation Research (MEDSIR)
  176. Megalabs
  177. Merck
  178. Millennium Pharmaceuticals
  179. Mitsubishi Gas Chemical
  180. Momenta Pharmaceuticals
  181. MorphoSys
  182. Mylan
  183. Nanexa
  184. Nektar Therapeutics
  185. NeuroDerm
  186. Nexus Pharmaceuticals
  187. Ningbo Zhengli Pharmaceutical Packaging
  188. Nippon Organon
  189. Nipro PharmaPackaging
  190. Novartis
  191. Novo Nordisk
  192. Octapharma
  193. Oncorus
  194. Otsuka Pharmaceutical
  195. Outlook Therapeutics
  196. PapiVax Biotech
  197. PCI Pharma Services
  198. Paige Biopharmaceutical
  199. Peptron
  200. Pfizer
  201. PharmaEssentia  
  202. PHC Injection Device Technologies
  203. Piramal Pharma
  204. Pisa Farmaceutica
  205. Plas-Tech Engineering
  206. Pluristem Therapeutics
  207. Polpharma Biologics
  208. Primequal
  209. Propella Therapeutics
  210. PTC Therapeutics
  211. Qindao Huaren Medical
  212. RAUMEDIC
  213. Regeneron
  214. Rejuven Dermaceutical
  215. Reliance Life Sciences
  216. Rentschler Biopharma
  217. RHEACELL  
  218. Roche
  219. Laboratorios Farmaceuticos Rovi 
  220. R-Pharm
  221. Sagar Rubber Products
  222. Samsung Bioepis
  223. Samsung BioLogics
  224. Samsung Medical Rubber
  225. Sandoz
  226. Sanofi
  227. Scancell
  228. SCHOTT
  229. SciPharm
  230. Secura Bio
  231. Seqirus
  232. Serina Therapeutics
  233. Serum Institute of India
  234. Sewa Medicals
  235. Shan Dong Boan Biotechnology (Acquired by Luye Pharma)
  236. Shandong Jihai Medical Technology
  237. Shandong Pharmaceutical Glass
  238. Shandong Weigao
  239. Shandong Zibo Minkang Pharmaceutical Packaging
  240. Shanghai Hengrui Pharmaceutical
  241. Sheng Zou Rubber & Plastics
  242. Shin Yan Sheno Precision Industrial
  243. Shire
  244. Shrinath Products (A Divison of Elmer Products)
  245. Siegfried Holding
  246. Splash Pharmaceuticals
  247. Square Pharmaceuticals
  248. SRI International
  249. SRK Pharmaceuticals
  250. STADA Arzneimittel
  251. Stealth BioTherapeutics
  252. Sumitomo Rubber Industries
  253. Sun Pharmaceutical Industries
  254. Sunshine Guojian
  255. Surecare Pharma
  256. Swedish Orphan Biovitrum
  257. Taizhou Kanglong Pharmaceutical Packing
  258. TaiMed Biologics
  259. Taisei Kako
  260. Taj Life Sciences
  261. Taj Pharmaceuticals
  262. Takeda
  263. Talecris Biotherapeutics
  264. Terumo
  265. Tetherex Pharmaceuticals  
  266. Teva Pharmaceuticals
  267. The Plasticoid Company
  268. Tip-Top
  269. Tolmar
  270. Toray Industries
  271. Transcoject
  272. Trinomab Biotech 
  273. UCB Biopharma
  274. Closed Joint Stock Company (CJSC) Unimed Laboratories
  275. United BioPharma
  276. Universal Medicap
  277. US WorldMeds
  278. Vetter Pharma
  279. VHB Medi Sciences
  280. Vighnesh Rubbers
  281. ViiV Healthcare
  282. VITARIS
  283. Weidmann Medical Technology
  284. West Pharmaceutical
  285. WuXi Biologics
  286. Xbiotech
  287. Xencor
  288. Xeris Biopharma
  289. YL Biologics
  290. Yuhan  
  291. Zealand Pharma
  292. Zen Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com